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Abstract 
Neuronal regulation of haematopoietic stem cell ageing and age-
related blood disorders through the microenvironment 
Ya-Hsuan Ho 
Haematopoietic stem cells (HSCs) give rise to all blood and immune cells in our body. Residing 
in the bone marrow (BM), HSCs are surrounded by numerous cell types and the associated 
extracellular matrix, which form a unique microenvironment known as ‘’HSC niche’’. 
Sympathetic neurons are important BM niche regulators, controlling HSC traffic in and out of 
the BM through the activation of β-adrenergic receptors (β-ARs). However, whether BM 
sympathetic-adrenergic signalling regulates other functions of HSCs remains poorly 
understood.    
Upon ageing, HSCs are functionally impaired, characterised by increased proliferation, 
decreased regenerative capacity, and myeloid/megakaryocytic-biased differentiation at the 
expense of lymphoid cell production. Ageing is associated with an increased risk to develop 
myeloid malignancies, but the contributions of HSC-intrinsic and -extrinsic ageing 
mechanisms remain debated. The current study aimed to understand how BM niches influence 
HSC fate in mouse models of ageing and age-related myeloid disorders, with a particular focus 
on microenvironmental regulation of myelopoiesis/megakaryopoiesis in response to neuronal 
inputs. During normal ageing, HSC niches decrease near bone but expand further from bone. 
Adrenergic signalling regulates lymphoid-myeloid balance during ageing. Whereas β2-AR 
promotes myeloid and megakaryocyte (Mk) differentiation through stromal-cell-derived 
interleukin-6 (IL-6), reduced β3-AR signalling accelerates ageing by remodelling HSC niches 
and diminishing lymphoid-biased HSCs. Similarly, non-HSC-autonomous premature 
haematopoietic ageing is observed in Hutchinson-Gilford progeria syndrome (HGPS). Chronic 
treatment of β3-AR agonist partially rejuvenates premature haematopoietic ageing in HGPS 
and restores exacerbated megakaryopoiesis in myeloproliferative neoplasms (MPNs).  
In summary, these results suggest that HSC niche remodelling and a functional switch of 
sympathetic activity (β2-AR overriding β3-AR) contribute to myeloid expansion during normal 
ageing. Certain ageing features in HGPS and aged-related pathological conditions could be 
improved by targeting the microenvironment. 
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1. Introduction 
1.1 Evolving concept of bone marrow (BM) haematopoietic 
stem cell (HSC) niches 
Adult haematopoiesis takes place in the bone marrow (BM), where 
haematopoietic stem cells (HSCs) can self-renew, proliferate and differentiate to 
replenish the blood and immune systems. Given that most HSCs are quiescent 
under homeostasis, mature blood and immune cell production is believed to 
derive mainly from progenitor cells (rather than HSCs), which undergo stepwise 
differentiation to produce specific blood and immune cell lineages, including 
myeloid lineage cells, consist of granulocytes, monocytes, megakaryocytes (Mks) 
(precursors of platelets) and erythrocytes, and lymphoid lineage cells, comprising 
T-cells, B-cells and natural killer cells. Cumulative studies have demonstrated 
that HSCs are heterogenous and contain subsets with distinct myeloid, platelet or 
lymphoid-biased potentials (Ema et al., 2014). Additionally, they have shown that 
HSCs can bypass the intermediate steps to generate mature progenies under 
certain conditions, such as chronic inflammation and ageing (Nishikii et al., 2017).  
 
Haematopoiesis is tightly controlled by cell-intrinsic mechanisms (lineage-
specific transcription factors and epigenetic modifications) and the surrounding 
microenvironment, known as “HSC niche”. Osteoblasts (bone-forming cells) and 
osteolineage are the first niche cells found to be involved in HSC regulation. Early 
studies have indicated that osteoblasts differentiated from BM stromal cells 
secrete haematopoietic cytokines and could maintain HSCs in culture (Taichman 
and Emerson, 1994). In 2003, two studies described for the first time that 
transplanted HSCs lodge near the bone surface (endosteum) in the BM, where 
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their numbers are regulated by osteoblastic cells. Dr. Zhang et al. showed that 
transplanted long-term (LT) HSCs adhere to spindle-shaped N-cadherin+CD45- 
osteoblastic (SNO) cells, which control the size of HSC pool by BMP signalling 
(Zhang et al., 2003). Dr. Calvi et al. reported that osteoblasts activated with 
parathyroid hormone/parathyroid hormone-related protein receptor (PPRs) 
produce high levels of Notch ligand Jagged 1 and increase HSC number (Calvi et 
al., 2003). Later studies by Dr. Suda’s group identified Tie2/angiopoietin-1 
signalling and thrombopoietin (TPO)/MPL signalling as important regulators of 
HSC quiescence through the interaction with osteoblasts (Arai et al., 2004; 
Yoshihara et al., 2007). High calcium concentration in the endosteum also plays 
an indispensable role in supporting HSCs, since calcium-sensing receptor (CaR) 
knockout HSCs fail to migrate to endosteal BM surface after transplantation 
(Adams et al., 2006). In addition, endosteal BM is reportedly enriched in C-X-C 
motif chemokine 12 (CXCL12) (Sugiyama et al., 2006) and stem cell factor (SCF) 
(Kinashi and Springer, 1994), two key HSC cytokines, strengthening the 
hypothesis that the endosteal BM is an important reservoir for HSCs. However, 
the concept of osteoblastic/endosteal niche was thereafter challenged by Dr. 
Morrison’s study, indicating that osteoblastic-specific deletion of CXCL12 or 
SCF only promotes the maintenance of early lymphoid progenitors but has little 
impact on HSCs (Ding and Morrison, 2013). Furthermore, N-cadherin in 
osteolineage cells seems to be dispensable for HSC maintenance under 
homeostasis (Greenbaum et al., 2012). These studies suggest that most HSCs are 
maintained in non-endosteal BM under steady state. Murine BM is highly 
vascularised, and the close developmental relationship between haematopoietic 
and endothelial lineages together suggest that HSCs are housed and regulated in 
perivascular regions. However, it is important to note that endosteal BM niches 
are densely vascularised. To date, at least two functionally distinct perivascular 
niches highly expressing CXCL12 and SCF have been identified: the peri-
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arteriolar niches, which contain Nestin-GFPbright and/or NG2+ mesenchymal 
stromal cells (MSCs), and the peri-sinusoidal niches, where sinusoid-associated 
CXCL12-abundant reticular cells (CAR), Nestin-GFPdim and/or Leptin receptor+ 
(LepR+) cells reside (Boulais and Frenette, 2015). Recent studies reveal that Mks 
also regulate HSC quiescence through transforming growth factor β (TGFβ), TPO 
and platelet factor 4 (PF4) secretion (Bruns et al., 2014; Nakamura-Ishizu et al., 
2014; Zhao et al., 2014). Given the complexity of the BM architecture and the 
limitations of current genetically-modified mouse models, it remains 
controversial which specialised niches predominantly regulate HSC quiescence. 
It is likely that HSC quiescence is regulated by different signals in distinct BM 
regions and during steady state or stress haematopoiesis. However, HSC lineage 
commitment appears to be highly influenced by the location. Accumulating 
evidence suggests that lymphopoiesis preferentially occurs near the endosteum, 
while myelopoiesis/erythropoiesis/megakaryopoiesis takes place at non-
endosteal regions. Supporting the concept, a recent study using von Willebrand 
factor (Vwf)-eGFP to label different HSC populations demonstrated that Vwf+ 
platelet/myeloid-biased HSCs are associated with Mks, whereas Vwf- 
lymphoid/non-biased HSCs are close to arterioles (Pinho et al., 2018). Therefore, 
alterations in specialised niches might directly affect myeloid/lymphoid output, 
and imbalanced production of mature haematopoietic cells at specific niches 
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Figure 1. BM HSC niches. 
HSCs are located at specialised ‘’niches’’ where their proliferation, 
differentiation and mobilisation are tightly controlled. BM niche components 
include mesenchymal stromal cells (MSCs), sympathetic neurons, non-
myelinating Schwann cells, endothelial cells, osteoblasts and mature 
haematopoietic progenies. Based on BM anatomy, HSCs are differentially 
regulated at endosteal niches (close to bone surface) and/or non-endosteal niches 
(away from bone surface). Given BM is highly vascularised, most HSCs are 
adjacent to different types of vessels. At least two functionally distinct 
perivascular niches have been identified: arteriolar niches and sinusoidal niches. 
This image has been reproduced from (Sanchez-Aguilera and Mendez-Ferrer, 
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1.2 Neuronal regulation of haematopoiesis in the BM 
The sympathetic nervous system (SNS) is one division of the autonomic nervous 
system (ANS) that participates in maintaining tissue homeostasis. Two types of 
neuron, the preganglionic neuron and the postganglionic neuron, are responsible 
for the transmission of SNS signals. Preganglionic fibres release acetylcholine, 
which activates nicotinic acetylcholine receptors on postganglionic neurons. In 
response to the stimulus, postganglionic fibres innervate targeted organs by 
locally releasing neurotransmitters, including dopamine, norepinephrine (NE) 
and epinephrine (EPI) (Feldberg, 1952). Sympathetic regulation of HSCs has 
been studied by Dr. Frenette‘s group, who reported that HSC egress and enforced 
mobilisation induced by granulocyte-colony-stimulating factor (G-CSF) is 
regulated by SNS signals in the BM (Katayama et al., 2006; Mendez-Ferrer et al., 
2010). One regulation involves BM Nestin-GFP+ MSCs, which are regulated by 
sympathetic nerve fibres via β3-adrenergic receptor (AR). This SNS-MSC 
regulatory axis regulates HSCs in part through chemokine CXCL12 (Mendez-
Ferrer et al., 2010). In contrast, activation of β2-AR can directly promote 
haematopoietic stem and progenitor cell (HSPC) mobilisation (Spiegel et al., 
2007), or indirectly induce clock gene expression by stromal cells (Mendez-
Ferrer et al., 2010). Another study has shown that sympathetic tone in the BM 
primes anti-HSC-mobilizing functions of neutrophils (Kawano et al., 2017). 
Recent studies from our group have uncovered the role of sympathetic cholinergic 
nerve fibres in the regulation of HSC and leukocyte traffic (Garcia-Garcia et al., 
2018). Although the regulation of HSC traffic by sympathetic nerve fibres has 
been well investigated, whether SNS regulates other functions of HSCs and/or 
their committed progenies remains largely unexplored.  
 
 










Figure 2. Sympathetic adrenergic regulation of HSC mobilisation by β-ARs. 
HSPCs trafficking is regulated by the sympathetic nervous system (SNS). 
Cooperation of β2-AR and β3-AR directly and/or indirectly (through Nestin-
GFP+ MSCs) controls HSPC egress to circulation and homing to BM. This image 










  7  
 
1.3  MKs and megakaryopoiesis and thrombopoiesis 
Mks are platelet precursors in the BM, 70% of which are found adjacent to 
sinusoids. Mks are 10-15 times larger than red blood cells but they account for 
only 0.01 % of total BM nucleated cells. Whereas the major function of Mks is 
to produce platelets for blood clotting, recent studies also indicate that Mks are 
necessary for regulating HSC quiescence (Bruns et al., 2014; Nakamura-Ishizu et 
al., 2015; Zhao et al., 2014). Megakaryopoiesis is a process by which HSCs 
proliferate and differentiate to the large polyploid Mks. The traditional view 
involves a hierarchy of several consecutive commitment steps, during which 
HSCs sequentially transition from multipotent progenitor (MPP), common 
myeloid progenitor (CMP), megakaryocyte-erythrocyte progenitor (MEP), Mk 
progenitor (MkP), to multilobulated Mk (Malara et al., 2015). However, this 
stepwise Mk differentiation from HSCs has been questioned by recent studies 
proposing different routes to make blood cells and demonstrating that Mks can 
arise directly from HSCs (Huang and Cantor, 2009; Woolthuis and Park, 2016). 
As Mks mature, they undergo endomitosis by constantly doubling the numbers 
of chromosomes in the nucleus without cytoplasmic division (Jackson, 1990). In 
addition, their cytoplasm expands, followed by the formation of demarcation 
membrane system (DMS) and increased numbers of α-granules (Schulze et al., 
2006). Terminally differentiated Mks migrate to the sinusoids for platelet release 
through a process called thrombopoiesis (Choi et al., 1996). Platelets are 
generated from the pseudopodial extensions of Mk, termed the proplatelets, 
which elongate along the endothelium and are fragmented by the bloodstream 













Figure 3. Megakaryopoiesis and thrombopoiesis. 
Megakaryopiesis and thrombopoiesis include multistep biological processes: 1) 
HSCs undergo lineage-specific commitment to megakaryocyte progenitor (MkP). 
2) MkPs differentiate to mature Mks. 3) Mature Mks migrate and adhere to the 
sinusoidal walls to generate platelets. The processes are tightly controlled by cell-
intrinsic factors (mainly lineage-specific transcription factors) and 
microenvironmental signals (mainly cytokines and chemokines, such as TPO, 
SCF, IL3, IL6, IL11 and CXCL12). 
 
Megakaryopoiesis and thrombopoiesis are controlled by microenvironmental 
cues and transcriptional factors (TFs). TPO, a glycoprotein cytokine primarily 
produced by the liver, is a master regulator of both processes (Vainchenker et al., 
2013). The chemoattractant stromal cell-derived factor 1 (SDF-1)/CXCL12 
directs Mk migration to the sinusoids for platelet production (Majka et al., 2000). 
GATA-1, FLI-1 and FOG play major roles in regulating HSC lineage 
commitment to Mk (Pimkin et al., 2014), whereas NFE-2 governs platelet 
biosynthesis (Tijssen and Ghevaert, 2013). The spatial regulation of 
megakaryopoiesis in murine BM is controversial. The standard model suggests 
that Mk precursors migrate from endosteum to sinusoids for maturation (Eto and 
Kunishima, 2016). A revised model suggests that Mks and MkPs both reside at 
the sinusoid niche where megakaryopoiesis and thrombopoiesis directly take 
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place (Kunisaki et al., 2013; Stegner et al., 2017). In either case, these studies 
highlight the importance of the interaction between Mks and the 
microenvironment. Although many studies have indicated that different 
neurotransmitters can affect platelets, whether megakaryopoiesis/thrombopoiesis 
are regulated by SNS signals remains elusive. One study has suggested that Mk 
maturation and platelet production are regulated by adrenergic signals in the BM 
(Chen et al., 2016). However, whether neuronal signals regulate HSC lineage 








Figure 4. The current model and revised model of megakaryopoiesis and 
thrombopoiesis. 
Traditional view suggests HSCs and MkPs migrate from endosteum to central 
marrow as they differentiate and mature to Mks. Current model suggests HSCs 
and MkPs are locating near sinusoids where megakaryopoiesis/thrombopoiesis is 






  10  
 
1.4  HSC ageing and the aged BM microenvironment 
Upon ageing, HSCs expand but their functions are impaired, characterised by 
reduced regenerative potential, decreased homing capacity and myeloid-biased 
differentiation at the expense of lymphopoiesis (Liang et al., 2005; Mohrin et al., 
2015; Rossi et al., 2005; Sudo et al., 2000). The functional decline of aged HSCs 
correlates with their loss of cell polarity, which is in part mediated by elevated 
activity of the small RhoGTPase Cdc42 (Florian et al., 2012). Other HSC-
intrinsic ageing drivers include DNA damage, reactive oxygen species (ROS)-
induced oxidative stress, metabolic alterations, impaired autophagy and 
epigenetic dysregulations (de Haan and Lazare, 2018; Lee et al., 2019). Ageing 
also impacts HSCs by changing their BM distribution. Aged HSCs have been 
reported to locate further away from the bone surfaces after BM transplantation 
(Florian et al., 2012), correlating with increased marrow HSC numbers and 
enhanced HSC mobilisation into circulation (Xing et al., 2006). Recent studies 
using whole-mount immunofluorescence staining of murine long bones further 
revealed that aged HSCs are more distant to the endosteum, arterioles, Nestin-
GFPhigh cells and Mks, but their distance to sinusoids and Nestin-GFPlow cells is 
unchanged compared to young HSCs (Maryanovich et al., 2018; Sacma et al., 
2019). These results suggest that BM microenvironment is altered with age, 
which might favour HSC lodging near non-endosteal/central niches (over 
endosteal niches). The following sections will discuss current studies on age-
related BM niche remodelling, key microenvironmental players and the 

















Figure 5. General features of HSC ageing. 
Compared to young HSCs, aged HSCs exhibit reduced regenerative capacity, 
skewed differentiation towards myeloid/megakaryocytic progenitors, increased 
mobilisation and redistribution further away from endosteum. (Image taken from 
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1.4.1 Dysfunction of BM MSCs during ageing 
 
Alteration of MSC populations during ageing 
Studies regarding the absolute number of MSCs during ageing are controversial, 
with some suggesting an overall increase (Garcia-Prat et al., 2013; Stolzing et al., 
2008) while others suggest unchanged numbers (Siegel et al., 2013; Wagner et 
al., 2009). It is noteworthy that MSCs are heterogeneous, and conventional 
markers to immunophenotypically define functionally distinct MSCs are lacking. 
Using Nestin-GFP to label a subset of murine MSC population, scientists have 
revealed that Nestin-GFP+ cells in endosteal BM are significantly decreased 
during ageing (Sacma et al., 2019), consistent with the reduction of arteriole-
associated αSMA+, PDGFRβ+ and NG2+ cells (Maryanovich et al., 2019). The 
age-related contraction of endosteal BM might initiate lymphoid deficiency at the 
level of HSCs, since lymphoid-biased HSCs seem to be enriched near bone, 
whereas more committed lymphoid lineage cells, such as common lymphoid 
progenitors and pro-B cells, localize near sinusoids (Balzano et al., 2019; 
Cordeiro Gomes et al., 2016; Ding and Morrison, 2013; Pinho et al., 2018). 
Functionally, old MSCs have lower colony-forming unit fibroblast (CFU-F) 
capacity in vitro and fail to produce HSC supporting molecules (Maryanovich et 
al., 2019). Revitalising MSCs with the ability to produce niche factors can prevent 
DNA damage in cultured HSCs (Nakahara et al., 2019).  
 
MSC differentiation potential is imbalanced during ageing 
MSCs exhibit reduced osteogenesis with age, which is associated with lower 
osteopontin (OPN) secretion to the extracellular matrix (Guidi et al., 2017). OPN 
negatively regulates HSC proliferation (Haylock and Nilsson, 2006; Nilsson et 
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al., 2005; Stier et al., 2005), and its decline might accelerate HSC divisions during 
ageing. Supporting this idea, treatment with thrombin-cleaved OPN partially 
reverses the age-associated phenotype of HSCs (Guidi et al., 2017). CC-
chemokine ligand 5 (CCL5), a pro-inflammatory cytokine involved in bone 
remodelling (Wintges et al., 2013), is reportedly increased with age. Researchers 
also reported a direct contribution of CCL5 to myeloid-biased differentiation at 
the cost of T cells (Ergen et al., 2012), suggesting that CCL5 is important for 
ageing of the haematopoietic system and the microenvironment. In contrast, old 
MSCs show adipocyte skewing (Kim et al., 2012). Adipocytes are a BM niche 
component that regulate hematopoiesis after irradiation or leukemia (Boyd et al., 
2017), although their roles negatively regulating HSC numbers (Naveiras et al., 
2009) and haematopoiesis under homeostasis seem to be dispensable (Zhou et al., 
2017). However, it has been reported that the functions of adipose tissues alter in 
response to ageing, such as ectopic lipid deposition, insulin resistance and 
increased inflammation (Mancuso and Bouchard, 2019).  Accumulation of BM 
adipocytes upon ageing not only reduces haematopoietic reconstitution, but also 
disrupts bone fracture repair (Ambrosi et al., 2017). The later likely contributes 
to the increased risk of osteoporosis and bone fracture in the elderly population 
(Fazeli et al., 2013; Schwartz, 2015). 
 
MSCs are senescent during ageing 
BM ageing is also associated with senescence of MSCs, evidenced by increased 
p53/p21-mediated DNA damage, upregulation of p16(INK4a) and elevated levels 
of ROS (Kornicka et al., 2015; Zhang et al., 2011; Zheng et al., 2013). Dr. Ju et 
al. discovered an age-dependent shortening of telomeres in Telomerase RNA 
component knockout (Terc-/-) MSCs, and lethally irradiated Terc-/- mice carrying 
wild-type BM cells display accelerated myelopoiesis (Ju et al., 2007). More 
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recently, proteomic analyses of human BM have unravelled nitric oxide (NO) 
synthesis and the urea cycle pathways as potential mediators for the crosstalk 
between old MSCs and HSCs (Hennrich et al., 2018). Murine MSCs highly 
express neuronal nitric oxide synthase (nNOS, encoded by gene NOS1), and 
NOS1-/- mice develop certain premature ageing features, such as increased 
peripheral platelets and granulocytes (Ho et al., 2019). Given the importance of 
NO in vascular biology and balanced inflammatory responses (Tripathi et al., 
2007), it is likely that NO pathways participate in the aged vascular remodelling 
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1.4.2 Remodelling of BM vasculature and its functions 
 
Alteration of endothelial cells (ECs) during ageing 
During ageing, a drastic remodelling of BM endothelial architecture occurs. 
Studies using whole-mount confocal imaging, two photon intravital microscopy 
and flow cytometry analysis, demonstrated an overall increase of vascular density 
in aged mice (Kusumbe et al., 2016; Maryanovich et al., 2019). Yet, distinct 
endothelial sub-populations behave differently with age. Arterioles are found to 
be decreased, while sinusoids appear to be unchanged upon ageing (Ho et al., 
2019). Supporting these observations, arteriole segments covered by Nestin-
GFPbright cells are found to be shortened (Maryanovich et al., 2019). Transitional 
zone vessels (TZVs) containing type-H endomucin (EMNC)-high ECs (which are 
enriched in the murine trabecular BM, where they support developmental bone 
growth (Kusumbe et al., 2014)), are reduced in old mice (Ho et al., 2019; 
Kusumbe et al., 2016). In contrast, small capillaries (CD31highEMCN- cells with 





Figure 6. Remodelling of BM vasculature during ageing. 
Whole-mount confocal imaging shows that TZVs (EMCNhiCD31hi endosteal 
vessels) are decreased, while small capillaries (CD31hiEMCN-, <6 μm diameter) 
are expanded in aged murine BM. (Image taken from Ho et al. Cell stem cell 2019. 
The staining was performed by Claudia Korn.)  
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The functions of ECs are compromised during ageing 
The functions of ECs decline with age, characterized by increased vascular 
leakiness, reduced NO production, increased ROS levels and decreased 
angiogenic potential (Poulos et al., 2017). Poulos et al. previously reported that 
purified HSCs from young mice cocultured with ECs from old mice fail to show 
long-term and multilineage reconstitution, while old HSCs cocultured with young 
ECs maintain their self-renewal ability (Poulos et al., 2017). Infusion of young 
ECs into aged, conditioned mice revives the old haematopoietic system. 
Kusumbe et al. identified high Notch activity in type-H ECs and the associated 
perivascular cells (Kusumbe et al., 2016), suggesting that contraction of endosteal 
vessels upon ageing occurs concomitantly with impaired Notch signalling. 
Overexpression of Notch ligand, DLL4 in vascular ECs is shown to prevent 
myeloid-skewing of haematopoietic progenitors (Tikhonova et al., 2019), despite 
DLL4 being undetectable or unchanged in aged BM (Sacma et al., 2019). 
Nevertheless, Sacma et al. observed that the levels of Jag2, another Notch ligand, 
are reduced in Nestin-GFPhigh/arteriolar cells with ageing. In contrast, Jag2 levels 
are higher in sinusoids/Nestin-GFPhigh cells, and Jag2 blockade induces 
proliferation and clustering of aged HSCs near sinusoids (Sacma et al., 2019). 
Together, these results strongly suggest that altered Notch signalling critically 
contributes to HSC ageing in different ways depending on the niche: in the 
endosteal vessels, Notch signalling appears to regulate HSC lineage commitment, 
whereas it is required in the sinusoids to preserve old HSCs (since HSCs 
accumulate in sinusoidal niches as a function of age). 
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1.4.3 Inflammation 
Ageing of the BM microenvironment is associated with increased pro-
inflammatory cytokines in mice and humans (Kovtonyuk et al., 2016). Several 
lines of evidence have indicated that inflammatory signals drive 
myeloid/megakaryocytic differentiation. In age-related myeloid malignancies, 
such as myeloproliferative neoplasms (MPNs) and chronic myelogenous 
leukaemia (CML), serum interleukin 1 β (IL-1β) and interleukin 6 (IL-6) levels 
are elevated (Arranz et al., 2014; Reynaud et al., 2011). Dr. Pietras et al. reported 
that chronic IL-1 exposure induces HSC myeloid skewing at the expense of self-
renewal (Pietras et al., 2016). IL-1α/β regulates thrombopoiesis in vitro (Beaulieu 
et al., 2014; Nishimura et al., 2015), possibly explaining high platelet counts in 
aged mice (Grover et al., 2016). Defective phagocytosis of macrophages during 
ageing induces acquisition of platelet-biased HSCs through IL-1β signalling 
(Frisch et al., 2019). IL-6 promotes thrombopoiesis either through a direct effect 
on BM Mk differentiation (Ho et al., 2019) or indirectly by upregulating hepatic 
TPO levels (Kaser et al., 2001). Dr. Yamashita et al. demonstrated that transient 
stimulation of tumour necrosis factor α (TNFα) prevents HSCs from necroptosis, 
and proposed that constitutive activation might lead to hyperproliferation of 
HSCs and exacerbated myelopoiesis in ageing and myeloproliferative disorders 
(Yamashita and Passegue, 2019). Mks express TGF-β to regulate HSC 
quiescence, while Mk-derived TGF-β also stimulates TPO synthesis by BM 
stromal cells to enhance megakaryopoiesis (Sakamaki et al., 1999). An elegant 
study by Dr. Haas et al. reported that acute inflammation induces proliferation of 
the stem cell-like Mk progenitor to quickly replenish platelet loss, and the process 
is in part mediated through the interferon (IFN) family (Haas et al., 2015).        
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Despite a well-known lymphocyte loss, only the proportion, but not absolute 
number of lymphoid-biased HSCs declines with age (Beerman et al., 2010). In 
fact, both platelet-biased and lymphoid-biased HSCs expand, alter gene 
expression programs and exhibit myeloid/platelet-skewing output (Grover et al., 
2016). These findings suggest a cell fate change of HSCs upon ageing, and the 
net outcome is an increase of myeloid/platelet compartment at the expense of 
lymphoid compartment. Two possible non-mutually exclusive explanations are:  
1) Different HSCs suffer the same genetic deformities upon ageing and/or 2) 
microenvironmental alterations specifically influence HSCs and direct their cell 
fate. Supporting the later, HSCs subpopulations have been found to respond 
differently to inflammatory challenge during ageing (Mann et al., 2018). 
Moreover, Dr. Montecino-Rodriguez et al. discovered that old lymphoid-biased 
HSCs recover their young lymphoid commitment potential when removed from 
the old microenvironment (Montecino-Rodriguez et al., 2019). Exogenous 
addition of IL-1 blocks lymphocyte differentiation from old lymphoid-biased 
HSCs, confirming the indispensable role of IL-1 in HSC cell fate decision. 
Consistently, Dr. Benjamin et al. demonstrated that IL-1 blockade is sufficient to 
restore age-dependent increase of megakaryocytic-biased HSCs in vitro (Frisch 
et al., 2019).  
 
However, whether BM inflammation is the cause or consequence of HSC ageing 
remains debated. It is notable that mature myeloid/megakaryocytic cells are a 
major source of inflammatory cytokines (Pietras, 2017). Exacerbated 
myelopoiesis during ageing might also remodel the BM microenvironment, 
favouring HSC myeloid/megakaryocytic-skewing through inducing 
inflammation. A positive feedback loop of cytokine storm created by HSCs, their 
progeny cells and the niche compartments contribute to HSC ageing and might 
further predispose myeloid malignancies.  
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1.4.4 Neuronal regulation by sympathetic adrenergic signalling 
It has been reported that BM sympathetic stimulation of β2-AR or β3-AR regulates 
HSC mobilisation (Mendez-Ferrer et al., 2010). A recent publication by Dr. 
Maryanovich et al. suggests that adrenergic nerve fibres marked with tyrosine 
hydroxylase (Th, rate-limiting enzyme in catecholamine synthesis) are reduced 
in old murine BM (Maryanovich et al., 2019). The study also indicates that 
surgical denervation of young BM induces premature ageing of the 
haematopoietic system, although certain experimental variables, such as the 
inflammation induced by the surgical denervation, might influence the observed 
phenotypes. Similar reduction of nerve fibres has been reported in a mouse model 
of the age-related MPNs (Arranz et al., 2014), suggesting that BM neuropathy 
might predispose to the development of myeloid malignancies with age. However, 
using whole-mount imaging and 3D reconstruction of different bones, other 
investigators from our group found that the BM area occupied by Th+ adrenergic 
fibres are actually doubled during normal physiological ageing (Ho et al., 2019), 
consistent with the well-known increase in sympathetic activity in the elderly 
(Hart and Charkoudian, 2014; Ng et al., 1993; Veith et al., 1986; Ziegler et al., 
1976). Additionally, the SNS has been known to control inflammation in a 
context-dependent manner (Pongratz and Straub, 2014). The concentration of 
catecholamines and the expressions of different ARs regulate the inflammatory 
state of the innate immune cells. Increased sympathetic activity during ageing 
might contribute to a cytokine storm by activating inflammatory cells, and 
subsequently affects lineage-bias of HSCs. Despite all the efforts made in recent 













Figure 7. Increased sympathetic nerve fibres during ageing. 
Whole-mount confocal imaging shows that Th+ sympathetic nerve fibres are 
increased in the skull of old mice compared to young mice. (Image taken from 
Ho et al. Cell stem cell 2019. The staining was performed by Justyna Rak and  
Andres Garcia-Garcia) 
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1.4.5 Other players in the BM microenvironment 
Emerging data suggest that the progenies of HSCs can feed back to regulate their 
activity under homeostasis, raising the possibility that mature haematopoietic 
cells (or their interactions with others) also contribute to HSC ageing. For 
instance, clearance of senescent CD62LlowCXCR4high neutrophils by 
macrophages has been reported to modulate HSC niches (Casanova-Acebes et al., 
2013). Dr. Frisch et al. discovered that aged macrophages are unable to engulf 
senescent neutrophils, leading to expansion of megakaryocytic-biased HSCs 
through IL-1β signalling (Frisch et al., 2019). Another key player is Mks, 
reportedly expressing PF4, CLEC-2, TPO and TGF-β to control HSC 
proliferation/quiescence (Bruns et al., 2014; Nakamura-Ishizu et al., 2014; 
Nakamura-Ishizu et al., 2015; Zhao et al., 2014). In murine BM, around 20% of 
HSCs are spatially associated with Mks (Bruns et al., 2014), and depletion of Mks 
expands platelet-biased HSCs (Pinho et al., 2018). BM Mks expand in ageing, 
and the distance of Mks to HSCs substantially increases (Maryanovich et al., 
2019), suggesting a remodelling of Mk niches with age. However, the mechanism 
by which age-related alterations of Mks regulate HSC ageing is still elusive. 
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1.5  Premature haematopoietic ageing in Hutchinson-
Gilford Progeria Syndrome (HGPS) 
In HGPS, aberrant splicing of LMNA gene (encoding both lamin A and lamin C) 
leads to nuclear assembly of the truncated protein, prelamin A (progerin) (De 
Sandre-Giovannoli et al., 2003; Eriksson et al., 2003). Certain hallmarks of 
haematopoietic ageing in mice, such as increased platelet counts, have been 
observed in HGPS (Merideth et al., 2008). Interestingly, cells ageing naturally 
also express increased levels of progerin (Scaffidi and Misteli, 2006), raising the 
possibility that normal physiological conditions and progeria might share similar 
ageing mechanisms. Dr. Grigoryan et al. recently reported that HSCs deficient of 
LMNA display premature ageing-like phenotype (Grigoryan et al., 2018), 
suggesting a prominent role of lamin A/C in haematopoiesis at the level of HSCs. 
The strong impact of progeria on growth and sexual maturation might be 
paralleled with its influences on HSCs, since growth hormones and sex hormones 
regulate HSC proliferation and lineage commitment (Heo et al., 2015; Stewart et 
al., 2014). However, it is unclear which lamin isoforms (A or C) are expressed by 
HSCs and whether HSCs express progerin. In this regard, it remains unknown 
whether premature haematopoietic ageing in HGPS exists and whether it is a 
consequence of progerin accumulation in HSCs, other haematopoietic cells 
and/or the microenvironment. LmnaG609G knock-in mice (LmnaG609G/G609G) 
display key features of the human disease, including accelerated ageing, 
shortened lifespan, and bone and cardiovascular defects (Hamczyk et al., 2018; 
Osorio et al., 2011; Villa-Bellosta et al., 2013). Our lab and collaborators have 
discovered that LmnaG609G/G609G mice exhibit myeloid/platelet-bias in the 
circulation, but the phenotype is not reproduced in wild-type (WT) recipients 
carrying LmnaG609G/G609G BM cells (Ho et al., 2019). These results suggest that 
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myeloid-skewing in progeroid mice might not be driven by HSC-autonomous 
defects.   
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1.6  Myeloproliferative neoplasms (MPNs) 
MPNs are blood disorders with uncontrolled expansion of haematopoietic and 
myeloid progenitor cells (Nangalia et al., 2016).  Three MPN subtypes, the 
polycythaemia vera (PV), essential thrombocythaemia (ET), and primary 
myelofibrosis (PMF) have been identified. PV is characterized by an elevation of 
red blood cells. ET is associated with high platelet counts in the peripheral blood 
concomitant with Mk hyperplasia in the BM. PMF is characterised by Mk 
hyperplasia and BM/spleen fibrosis, extramedullary haematopoiesis and 
leucocytosis (Vytrva et al., 2014). It has been reported that Mks in ET and PMF 
share common features, including atypical cluster formation, endosteal 
translocation and dysregulation of intrinsic pathways (Malherbe et al., 2016).  
However, the morphology of Mks is largely different in the two MPN subtypes. 
Mks in ET are reported to be giant, with staghorn-like nuclei, whereas Mks in 
PMF appear to be immature, characterized by cloud-shape nuclei and high 
nuclear/cytoplasmic ratio (Thiele et al., 2011). Emerging evidence has indicated 
that the increased numbers of Mks lead to myelofibrosis (Bain, 2010). Through 
the interaction with the BM niches, the pro-inflammatory cytokines TGF-β, 
PDGF, and bFGF are released from Mk α-granules and stimulate fibrotic tissue 
formation and osteoclerosis (Agarwal et al., 2016).  These observations suggest 
that aberrant Mk phenotypes are a hallmark of MPNs and that abnormal 
megakaryopoiesis plays critical roles in MPN pathogenesis. 
 
MPNs are driven by somatic mutations in the HSC compartment. A point 
mutation of G>T at the 617 position in exon 14 of the gene JAK2 (janus kinase 
2) is a hallmark of MPNs. The majority of MPN patients are found with 
JAK2(V617F) mutation, with a frequency of 95 % in PV and 50-60 % in ET and 
PMF. Other mutations, such as CALR and MPL, are only specific to ET and PMF 
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patients (Kim et al., 2015) and similar to JAK2 mutations involve constitutive 
JAK-STAT activation. Despite acquired mutations being the main drivers of 
MPNs, the fact that PV and ET may develop into PMF suggests that disease 
progression also pivots on microenvironment. Accumulating evidence has 
indicated that malignant HSCs can alter the BM microenvironment, favouring 
disease progression (Korn and Mendez-Ferrer, 2017). This raises the possibility 
of targeting HSC niche in MPN therapy. In 2014, a paper published by our group 
demonstrated that neuropathy of HSC niche triggered by mutant HSCs 
contributes to MPN pathogenesis (Arranz et al., 2014).  Sympathetic nerve fibres 
and Nestin-GFP+ cell numbers are found to be significantly reduced in MPN 
patients and MPN murine model. Time-course analysis indicated that impaired 
SNS precedes apoptosis of Nestin-GFP+ cells. Co-culture experiments in vitro 
further confirmed that IL-1β is responsible for neuroglial damage, which 
diminishes the number of Nestin-GFP+ cells. Disease acceleration (particularly 
increased Mk expansion leading to myelofibrosis) was found upon nestin+ cell 
depletion or in β3-AR-deficient mice, suggesting that loss of β3-AR or 
compromised Nestin-GFP+ cells stimulates MPN progression. Strikingly, chronic 
treatment with neuroprotective agent or β3-AR agonist blocks MPN progression 
in mice, as evidenced by reduced BM fibrosis and restored platelet/leukocyte 
counts in the peripheral blood. These results shed light on the idea that MPN 
progression is not only caused by HSCs alone, but also by alterations of the HSC 
niche. Improved reticulin fibrosis correlated with rescue of Nestin-GFP+ niches 
has been recently reproduced in a multicentre Phase-II clinical study addressing 
the possible use of β3-AR agonists in MPN patients (Drexler et al., 2019), but this 
treatment did not change mutant allele burden over 6 months. Overall, these data 
suggest that compensation of BM neuropathy might be a novel therapeutic 
strategy for MPNs. Nevertheless, how the unique neuro-MSC circuit affects 
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Figure 8. Neuropathy of BM microenvironment is essential for MPN 
progression. 
Mutant HSC-derived IL-1β causes BM glial and neural damage, leading to 
Nestin-GFP+ MSC apoptosis and accelerating disease progression. (Image taken 
from Arranz et al. Nature 2014.)   
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2. Rationale 
Haematopoiesis is tightly controlled by HSC-intrinsic mechanisms and the 
microenvironmental cues under both homeostasis and stress conditions. The SNS 
controls HSC traffic through activating β-ARs and nicotinic receptors, but 
whether other HSCs functions are regulated in response to neuronal inputs is 
poorly understood.  A recent publication reports that BM Th+ sympathetic nerve 
fibres are decreased in old mice, and sympathetic denervation results in 
haematopoietic ageing in a β3-AR-dependent manner. However, our group found 
increased BM sympathetic nerve fibres during ageing, which is consistent with 
the well-known increase of sympathetic activity in the elderly. The present study 
thus aims to investigate the roles of the BM microenvironment and its neural 
regulation in murine haematopoiesis during ageing and age-associated MPNs. 
The study will focus on addressing HSC myeloid/megakaryocytic-biased 
differentiation, and further extend the findings from normal physiological ageing 
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3. Materials and Methods 
 
3.1 Mouse strains 
Young (or adult) mice were analysed between 8-30 weeks of age, and old mice 
were 66-120 weeks old. Mice were housed in specific pathogen free facilities. All 
experiments using mice followed protocols approved by the Animal Welfare 
Ethical Committees, according to EU and United Kingdom Home Office 
regulations (PPL 70/8406). Nes-gfp (Mignone et al., 2004), Adrb2-/- 
(Chruscinski et al., 1999), FVB/N-Adrb3tm1Lowl/J (Susulic et al., 1995), 
Lmnatm1.1Otin (Osorio et al., 2011), Vwf-eGFP (Sanjuan-Pla et al., 2013), 
B6.129S4- Nos1tm1Plh/J (stock#2986) (Huang et al., 1993), B6.129S2-
Il6tm1Kopf/J (stock#2650) (Kopf et al., 1994) (Jackson Laboratories), Mx1-
cre;JAK2-V617 (Arranz et al., 2014), Tg(CAG-DsRed*MST)1Nagy/J (Stock No: 
005441, Jackson Laboratories) and congenic CD45.1 and CD45.2 C57BL/6 mice 
(Charles River Laboratories) were used in this study. 











Table 1. List of mouse strains. 
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3.2 Mouse studies 
3.2.1 Reverse chimera experiments of WT, Adrb2-/- or Adrb3-/- mice 
To generate chimeric mice carrying Adrb2-/- or Adrb3-/- BM cells, two-month-old 
C57BL/6 mice were lethally irradiated (12 Gy, two split doses) and i.v. 
transplanted with 2 X 106 nucleated BM cells from two-month-old WT, Adrb2-/-
or Adrb3-/- mice. To test microenvironment-dependent effects of β-adrenergic 
signalling, WT, Adrb2-/- or Adrb3-/- (CD45.2) mice were lethally irradiated (12 
Gy, two split doses) and i.v. transplanted with 2 X 106 nucleated BM cells from 
CD45.1 C57BL/6 mice. Haematopoietic cells in the BM were analysed 4 months 
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3.2.2 Chronic treatment of progeroid mice with β3-AR agonist  
For progeria studies, the selective β3-AR agonist BRL37344 (Sigma, St. Louis, 
MO) was administered at 2mg/kg through intraperitoneal (i.p.) injection once per 
day. Vehicle (saline solution) daily injections were performed in the same way. 
Treatment was initiated when LmnaG609G/G609G mice were 7 weeks old and lasted 
for 8 weeks. The experiment was collaboratively performed by Cristina 
Gonzalez-Gomez (research assistant in Vicente Andres’s group, Centro Nacional 
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3.2.3 Chronic treatment of MPN mice with β3-AR agonist  
For MPNs studies, Mx1cre;JAK2 (V617F) mice were given selective β3-AR 
agonist BRL37344 (Sigma, St. Louis, MO) at 2mg/kg through intraperitoneal (i.p.) 
injection twice per day. Vehicle (saline solution) daily injections were performed 
in the same way. Treatment lasted for 2 months. WT or Adrb3-/- mice were 
lethally irradiated (12 Gy, two split doses) and i.v. transplanted with 2 X 106 
nucleated BM cells from Mx1cre;JAK2 (V617F) mice. The experiments were 
performed by Dr. Lorena Arranz (previous postdoctoral associate in the lab). 
Long bones were taken for immunofluorescence of Mks, performed by the author 
of this thesis. H&E staining was performed by the pathologists, and the sections 





Figure 11. Scheme of MPN mice treated with β3-AR agonist, or β3-AR 
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3.3 Human studies 
The SAKK 33/14 trial (NCT02311569) was planned and conducted in 
accordance with the Declaration of Helsinki, the Guidelines for Good Clinical 
Practice (GCP) issued by ICH and requirements of the respective national 
regulatory authorities. The local ethics committees of all participating centres 
gave approval to the trial and written informed consent was obtained from all 
patients prior to enrolment. Immunohistochemistry was performed by the 
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3.4 Murine BM cell extraction and flow cytometry analysis  
Endosteal (e) and non-endosteal (n-e) BM fractions were isolated and analysed 
separately in this study, unless otherwise specified. Murine long bones were 
flushed gently to obtain single cell suspensions less tightly associated with the 
bone, which contain non-endosteal haematopoietic cells. The flushed-bones were 
then crushed in a mortar and filtered through a 40-mm strainer to obtain endosteal 
haematopoietic cells. Cells from both fractions were depleted of red blood cells 
by lysis in 0.15M NH4Cl for 10 min at 4℃. Cells were incubated with the 
appropriate dilution (2-5 mg/ml) of fluorescent antibody conjugates and 4’,6-
diamidino-2-phenylindole (DAPI) for dead cell exclusion, and analysed on 
LSRFortessa flow cytometer (BD Biosciences, Franklin Lakes, NJ) equipped 
with FACSDiva Software (BD Biosciences). The following antibodies were used: 
fluorescent CD45.1 (A20), CD45.2 (104), B220 (RA3-6B2), CD11b (M1/70), 
CD3ε (145-2C11), Ly-6G (1A8), sca-1 (E13-161.7), biotinylated lineage 
antibodies (CD11b, Gr-1, Ter119, B220, CD3ε) (BD Biosciences), c-kit (2B8) 
(eBioscience), CD150 (TC15-12F12.2), CD34 (RAM34) and CD41 (MWReg30) 
(BioLegend). Biotinylated antibodies were detected with fluorochrome 
conjugated streptavidin (BD Biosciences). Long-term HSCs (LT-HSCs) are 
immunophenotypically defined as lin-sca-1+c-kit+CD34-CD150+CD41- cells. 
Myeloid-biased HSCs are immunophenotypically defined as lin-sca-1+c-
kit+CD34-CD150+CD41+ cells. Lymphoid-biased HSCs are 
immunophenotypically defined as lin-sca-1+c-kit+CD34-CD150-CD41- cells. 
CD41+ LSK cells are immunophenotypically defined as lin-sca-1+c-kit+CD41+ 
cells. MkPs are immunophenotypically defined as lin-sca-1-ckit+ CD150+CD41+ 
cells. Granulocytes are immunophenotypically defined as CD45+Ly-6G+CD11b+ 
cells. B lymphocytes are immunophenotypically defined as CD45+B220+ cells. 
 






Figure 12. Scheme of endosteal and non-endosteal BM isolation from mouse 
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Antibody (clone) Supplier Dilution 
CD45.1 (A20) BD Biosciences 1:200 
B220 (RA3-6B2) BD Biosciences 1:200 
CD11b (M1/70) BioLegend 1:200 
CD3ε (145-2C11) TONBO Biosciences 1:200 
Ly-6G (RB6-(C5) BioLegend 1:200 
sca-1 (E13-161.7) BioLegend 1:200 
biotinylated lineage 
antibodies (CD11b, Gr-1, 
Ter119, B220, CD3ε) 
BD Biosciences 1:100 
c-kit (2B8) eBioscience 1:200 
CD150 (TC15-12F12.2)  BioLegend 1:200 
CD34 (RAM34) BD Biosciences 1:100 
CD41 (MWReg30) BioLegend 1:200 




Table 2. List of antibodies used for flow cytometry.  
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Megakaryocyte differentiation
HPC-7 4 days after coculture with MS-5
3.5 Cell culture 
3.5.1 HPC-7 cells coculture with MS-5 stromal cells 
HPC-7 cells were maintained in IMDM medium supplemented with 10% FCS 
and 100 ng/ml of mSCF (PeProTech 250-03). MS-5 cells were maintained in α-
MEM medium supplemented with 10% FCS. To induce Mk differentiation, HPC-
7 cells were cultured with or without MS-5 stromal cells in StemSpan H3000 
medium, supplemented with 50 ng/ml of TPO (PeProTech 300-18) and 2U/mL 
of erythropoietin (EPO) (R&D 287-TC-500) up to 4 days. 10 mM of BRL37344 
(β3-AR agonist; Sigma B169), 10 mM of clenbuterol (β2-AR agonist; Sigma 
C5423), 5 mM of H-89 (Protein kinase A inhibitor; Sigma B1427) and vehicle 
controls were added to the culture. To examine Mk differentiation, cells were 
incubated with anti-c-kit-FITC antibody (1:200, BD PharMingen 553354) and 
anti-CD41-PE antibody (1:200, BD PharMingen 558040). DAPI was added at 
1:10,000 to discriminate dead cells. Samples were analysed by Gallios flow 
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3.5.2 Human cord blood-derived HSPCs coculture with MS-5 
stromal cells 
Human umbilical cord blood CD34+ HSPCs were isolated using a CD34 
Microbead kit (Miltenyi Biotec 130-046-702) following manufacturer’s 
instructions, and were cultured with MS-5 stromal cells in Cellgro medium 
(CellGenix cat. no. 20802-0500), supplemented with 50 ng/ml of TPO 
(PeProTech 300-18) and 5 ng/ml of IL-1β (Cellgenix 1411-050) for 7-10 days, 
during which vehicle, 10 mM of BRL37344 (β3-AR agonist; Sigma B169) or 10 
mM of clenbuterol (β2-AR agonist; Sigma C5423) were added to the culture. 
Cellgro medium was refreshed at day3 and day7 of the coculture. To examine Mk 
differentiation, cells were fixed and stained with anti-human CD61 antibody 





Figure 15. Scheme of human cord blood-derived CD34+ HSPCs coculture 





Day 0 Day 3 Day 7 Day 10
Condition medium: Cellgro + 50 ng/mL TPO + 5 ng/mL IL-1β
+ vehicle or 10 µM β2-AR ag. or 10 µM β3-AR ag.
Add 1 mL of
condition medium
Refresh 1 mL of
condition medium IHCCD34+ hHSPC
Add 1 L of 
me ium 
Refresh 1 mL of 
medium 
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3.5.3 Lin- haematopoietic progenitors coculture with young and old 
primary murine stromal cells  
Haematopoietic progenitors were immunomagnetically enriched from 
DsRed;Vwf-eGFP mouse BM by using lineage depletion cocktail (BD 
Biosciences). To isolate primary stromal cells, long bones from young or old mice 
were crushed with PBS in a mortar. Cell fractions were digested in 2 ml of 
collagenase type I (Stem Cell Technologies, cat. No. 07902) for 30 min at 37℃ 
with agitation. The enzyme was quenched by adding 18 ml PBS/2%FCS. Cell 
suspensions were filtered, pelleted and red blood cell lysis was performed as 
stated above. Cells were then cultured in α-MEM medium supplemented with 
20% FCS for at least 14 days until a confluent culture was formed. Lin- 
haematopoietic progenitors were cocultured with primary stromal cells in Cellgro 
medium (CellGenix cat. no. 20802-0500), supplemented with 50 ng/ml of TPO 
(PeProTech 300-18) and 5 ng/ml of IL-1β (Cellgenix 1411-050) for 4 days, 
during which vehicle or 10 mM of clenbuterol (β2-AR agonist; Sigma C5423) 
were added to the culture. Mk differentiation was examined by the frequency of 
DsRed+Vwf-eGFP+ cells in total DsRed+ cells. Samples were analysed by 





Figure 16. Scheme of Lin- haematopoietic progenitors coculture with young 
or old stromal cells. 
  39  
 
3.5.4 Long-term mouse BM primary culture  
For mouse BM long-term culture, femurs and tibias were flushed gently to obtain 
BM cells. Cells were seeded and cultured in MyeloCult M5300 medium 
(StemCell Technologies, cat. no. 05350) supplemented with 106 M 
hydrocortisone (Stem-Cell Technologies, cat. no. 07904) at 33℃ for 14 days. 
Half of the medium was refreshed at day 7. At day 14 of culture, half of the 
medium was refreshed again, supplemented with 50 ng/ml of TPO (PeProTech 
300-18) for extra 4 days, during which vehicle, 10 mM of BRL37344 (β3-AR 
agonist; Sigma B169), 10 mM of clenbuterol (β2-AR agonist; Sigma C5423), or 
100 mM of L-VINO (Insight Biotechnology 728944-69-2) were added to the 
culture. At day 18 of culture, cells were collected and subjected to flow cytometry 











Day 0 Day 14 Day 18
Condition medium: Myelocult M5300 + 10-6 M hydrocortisone
Add 50 ng/mL TPO +/- vehicle or
10 µM β2-AR ag. or 10 µM β3-AR










Chemical/Cytokine Supplier Final 
concentration 
mSCF PeProTech 100 ng/ml 
TPO PeProTech  50 ng/ml 
EPO R&D 2U/mL 




BRL37344 (β3-AR agonist) Sigma-Aldrich 10 mM 
H-89 (PKA inhibitor) Sigma-Aldrich  5 mM 
Clenbuterol hydrochloride (β2-AR 
agonist) 
Sigma-Aldrich 10 mM 
L-VINO (Nos-1 inhibitor) Insight 
Biotechnology 
100 mM 
Table 3. List of chemicals/cytokines used for in vitro culture. 
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3.6 Immunofluorescence staining 
Murine long bones were isolated and quickly fixed in 2% paraformaldehyde (PFA) 
solution overnight at 4℃. Tissues were rinsed with PBS, and decalcified in 0.25 
M ethylenediaminetetraacetic acid (EDTA) solution at 4℃ for 14 days. After 
decalcification, tissues were cryo-preserved with 15% sucrose solution for 12 h 
at 4℃, followed by 30% sucrose solution for 12 h at 4℃. After cryopreservation, 
tissues were embedded in optimal cutting temperature (OCT) compound, and 
subjected to cryosection. Immunofluorescence staining of cryostat sections was 
performed as previously described (Isern et al., 2014), with minor modifications. 
Briefly, whole-mount thick sections or thin sections were blocked with TNB 
buffer (0.1 M Tris–HCl, pH 7.5, 0.15 M NaCl, 0.5% blocking reagent, Perkin 
Elmer) for 1 h at RT. Primary antibody incubations were conducted for 2 h at RT 
or overnight at 4℃. Secondary antibody incubations were conducted for 1 h at 
RT. Repetitive washes were performed with PBS or PBS + 0.05% Triton X-100. 
Stained samples were counterstained for 10 mins with 5 mM DAPI and rinsed 
with PBS. Slides were mounted in Vectashield Hardset mounting medium 
(Vector Labs) and sealed with nail polish. Whole-mount tissues were stored in 
PBS. Details of specific staining used in this study are described below:  
 
3.6.1 Whole-mount immunofluorescence staining of murine BM 
vasculature  
For whole mount staining of vasculature, tibia or femur BM thick sections were 
obtained with a cryostat and remaining OCT was removed by PBS washes. 
Samples were blocked and permeabilized in 0.1% Triton X-100 (Sigma) TNB 
overnight at 4℃. On the next day, samples were incubated with goat anti-CD31 
(R&D AF3628 1:100), and rat anti-EMCN (Insight Biotechnology sc-65495 
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1:100) diluted in 0.1% Triton X-100 TNB overnight at 4℃. Samples were rinsed 
with 0.05% Triton X-100 PBS for 8 hours and incubated overnight with 
secondary antibodies, including Dylight650 donkey anti-rat IgG (Thermo Fisher 
SA5-10029; 1:300) and Cy3-donkey anti-goat IgG (Jackson 705-165-147, 1:300) 
diluted in TNB. Samples were rinsed with 0.05% Triton X-100 PBS for 4 hours, 
washed with PBS and counterstained with DAPI (Sigma; 1:1000) to label cell 
nuclei. Images were acquired with Leica SP5 confocal microscope using 10x 
objectives and analysed with ImageJ. At least 3 independent and randomly 
selected BM areas were imaged and analysed per sample. For quantification of 
sinusoidal vessel area, EMCN+ area >150 mm distant to the bone surface was 
measured and normalized to BM area. Arteriolar (> 6 mm diameter) and capillary 
(< 6 mm diameter) CD31hiEMCN- vessel number was counted and normalized to 
BM area. To quantify TZVs, CD31hiEMCNhi area < 150 mm close to the bone 
surface was quantified and normalized to the bone surface length.  
 
3.6.2 Immunofluorescence staining of murine BM Mks and MkPs 
For staining of Mks and MkPs, BM femur thin sections were blocked with TNB 
for 1h at RT. Samples were then incubated with primary antibodies for 2 h at RT 
or overnight at 4C, followed by secondary antibodies incubation for 1h at RT. 
Finally, samples were counterstained with DAPI to label cell nuclei. Repetitive 
washes were performed with PBS. At least 3 independent and randomly selected 
BM areas were imaged and analysed by ImageJ. The following primary 
antibodies were used: CD41 (1:200, PE conjugated rat monoclonal antibody, BD 
PharMingen 558040), CD42d (1:100, APC conjugated armenian hamster 
monoclonal antibody, eBioscience 17-0421-80) and c-kit (1:100, goat polyclonal 
antibody, R&D AF1356). The following secondary antibodies were used: Alexa 
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Fluor 647 Goat-anti-armenian hamster IgG (1:200, Abcam ab173004) and Alexa 
Fluor 647 donkey-anti-goat IgG (1:200, Life Technologies A21447). 
 
3.6.3 Immunofluorescence staining of murine BM Mks and 
vasculature 
For staining of Mk localization relative to sinusoids, BM femur thin sections were 
blocked with 0.1% Triton X-100 TNB for 1h at RT. Samples were then incubated 
with rat anti-EMCN (Insight Biotechnology sc-65495 1:100) antibody diluted in 
0.1% Triton X-100 TNB overnight at 4℃. On the next day, samples were 
incubated with Alexa Fluor 647 goat-anti-rat IgG (1:200, Life Technologies, cat. 
no. A21247) secondary antibody for 1h at RT, followed by rat serum blocking 
(1:10 rat serum in 0.05% Triton X-100 TNB) for 10 min. Samples were incubated 
with third antibody, CD41 (1:200, PE conjugated rat monoclonal antibody, BD 
PharMingen 558040) for 2h at RT. Finally, samples were counterstained with 
DAPI to label cell nuclei. Repetitive washes were performed with PBS or 0.05% 
Triton X-100 PBS. At least 3 independent and randomly selected BM areas were 
imaged and analysed by ImageJ. 
 
3.6.4 Immunofluorescence staining of murine BM Mks and HSCs 
For HSCs and Mks staining, BM femur thin sections were blocked with TNB for 
1h at RT and followed by Avidin/biotin blocking. Samples were then incubated 
with rat anti-CD150 (1:50, Biolegend Cat. No. 115902) and Armenian hamster 
anti-CD42d (1:100, eBioscience 17-0421-80) primary antibodies overnight at 
4℃. On the next day, samples were incubated with Alexa Fluor 555 goat-anti-rat 
IgG (1:200, Life Technologies A21434) and Alexa Fluor 647 Goat-anti-armenian 
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hamster IgG (1:200, Abcam ab173004) secondary antibodies for 1h at RT, 
followed by rat serum blocking (1:10 rat serum in TNB) for 10 min. Samples 
were re-stained with biotinylated lineage antibodies (1:100, BD Biosciences) for 
2h at RT. Finally, samples were incubated with Alexa Fluor 488 Streptavidin-
conjugated antibody (1:200, Invitrogen S32354) for 1h at RT and counterstained 
with DAPI to label cell nuclei. At least 3 independent and randomly selected BM 
areas were imaged and analysed by ImageJ. 
 
3.6.5 Immunofluorescence staining of human Mks in coculture 
For staining of human cord blood-derived CD34+ HSPC co-culture, cells were 
fixed with 1%PFA for 20mins at RT. After PBS washes, cells were blocked with 
10% donkey serum (SigmaD9663) diluted in PBS for 1h at RT, followed by 2h 
incubation of mouse anti- human CD61 primary antibody 
(1:500,SerotecMCA728). After PBS washes, cells were incubated with Alexa 
Fluor 546 donkey-anti mouse IgG (1:200, Life Technologies, cat. no. A10036) 
secondary antibody for 1h at RT. Finally, samples were counterstained with DAPI 
to label cell nuclei. 10 independent and randomly selected fields in culture wells 
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Antibodies Supplier Dilution 
rat anti-CD150 antibody Biolegend  1:50 
Alexa Fluor 647 goat anti-rat IgG Life Technologies  1:200 
rat anti-EMCN antibody Insight 
Biotechnology 
1:100 
goat anti-CD31 antibody R&D 1:200 
Alexa Fluor 546 Donkey anti-rabbit 
IgG 
Invitrogen 1:200 
Dylight650 donkey anti-rat IgG Thermo Fisher 1:300 
Cy3-donkey anti-goat IgG Jackson  1:300 
Rat anti-CD41 (PE conjugated) 
antibody  
BD Pharmingen 1:200 
Alexa Fluor 647 donkey-anti-goat 
IgG 
Life Technologies 1:200 
Alexa Fluor 647 Goat-anti-armenian 
hamster IgG  
Abcam  1:200 
mouse-anti-human CD61 primary 
antibody 
Serotec 1:500 
Alexa Fluor 546 donkey-anti-mouse 
IgG 
Life Technologies 1:200 
Alexa Fluor 488 Sreptavidin-
conjugated antibody 
Invitrogen 1:200 
Alexa Fluor 555 goat-anti-rat IgG Life Technologies 1:200 
Human/Mouse CD117/c-kit 
Antibody (Polyclonal Goat IgG) 
R&D 1:100 
APC conjugated anti-mouse/rat 
CD42d antibody (armenian hamster 
IgG)  
eBioscience 1:100 
Table 4. List of antibodies for immunofluorescence staining. 
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3.7 RNA isolation and qPCR 
RNA isolation was performed using Trizol Reagent (Sigma T9424). Reverse 
transcription was performed using the High-Capacity cDNA Reverse 
Transcription kit (Applied Biosystems 4368814), following the manufacturer’s 
recommendations. qPCR was performed using the PowerUp SYBR Green Master 
Mix (Applied Biosystems A25742) and ABI PRISM7900HT Sequence Detection 
System. The expression level of each gene was determined by using the absolute 
quantification standard curve method. All values were normalized with Gapdh as 
endogenous housekeeping gene. 









Table 5. List of qPCR primer sequences.  
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3.8 Enzyme-linked immunosorbent assay (ELISA) 
MILLIPLEX MAP Mouse Cytokine/Chemokine Magnetic Bead Panel 
(MCYTOMAG-70K, Merck Millipore) was performed following the 
manufacture’s protocol. BM extracellular fluids of mouse long bones were 
collected from the supernatants following BM extraction and subjected to the 
mouse cytokine panel. 
 
3.9 Measurement of nitrate concentration 
NO(x) content was measured in freshly-thawed samples (BM extracellular fluids) 
that had been kept at -80℃ for less than 2 months using a nitric oxide analyser 
(NOA) 280i (Siever, GE Healthcare) according to the manufacturer’s instructions. 
Data were collected, processed and analysed by using liquid software (Siever, GE 
Healthcare). Samples were prepared by the author of this thesis, and the 
measurement was performed by Dr. David Macias (research associate in Randall 
S. Johnson’s group, University of Cambridge). 
 
3.10 Statistical analyses 
Statistical analyses and graphics were carried out with GraphPad Prism 7 
software. 
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4. Results 
4.1 Ageing inflames the BM microenvironment 
Investigators (Dr. Justyna Rak, Claudia Korn and Andres Garcia-Garcia) from 
our lab have demonstrated that BM HSC-supporting niches remarkably alter with 
age: reduction of endosteal niches, characterised by impaired endosteal vessels, 
arterioles and their associated Nestin-GFP+ cells; expansion of non-endosteal 
neurovascular niches, characterised by increased central small capillaries, their 
associated Nestin-GFP+ cells and Th+ sympathetic nerve fibres. It has been 
suggested that ageing and inflammation share similar haematopoietic alterations, 
such as myelopoiesis overriding lymphopoiesis. This myeloid dominance could 
be a trigger and/or consequence of increased inflammatory cytokines. 
Upregulation of circulating IL-6, TNFα, IL-1Rα, and C-reactive protein has been 
reported in the elderly. Increased inflammatory cytokines are known to happen in 
the circulation, but whether their concentrations follow spatial distribution in 
different BM niches during ageing has not been directly tested. To address this 
question, long bones from young and old mice were acquired, subjected to 
endosteal and non-endosteal BM separation (see section 3.4). Extracellular fluids 
from both BM fractions were extracted, and the concentration of inflammatory 
cytokine were measured by milliplex ELISA. In aged mice, the levels of IL-1α 
and IL-1β are significantly increased (Fig. 18A, C, H, H). IL-6 levels are elevated 
in endosteal BM (Fig. 18B and G), while IL-3 and IFNγ show similar trends (Fig. 
18D, E, I and J). These results suggest that ageing not only up-regulates 
inflammatory cytokines in the circulation, but it also inflames the BM 
microenvironment, which might directly impact haematopoiesis.   
 
 

















Figure 18. Ageing correlates with BM inflammation.  
(A–J) Concentration of (A, F) IL-1b, (B, G) IL-6, (C, H) IL-1a, (D, I) IL-3, and 
(E, J) IFNγ in endosteal BM (A-E) or non-endosteal BM (F-J) extracellular fluid 
(BMECF) from young WT mice (n = 5) and old WT mice (n = 4). Data are means 
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4.2 β-adrenergic signalling regulates megakaryopoiesis 
during ageing 
Given that BM Th+ fibres are expanded in aged mice, it is hypothesised that 
increased noradrenergic signalling might contribute to HSC ageing. To test the 
hypothesis, young and old mice lacking β2- and β3-ARs, two of the most 
important receptors transducing sympathetic nerve signals in the BM, were 
studied. Compared to young mice, old mice exhibit elevated platelet counts and 
increased frequency of peripheral granulocytes/monocytes paralleled with 
decreased percentage of lymphocytes in white blood cells, which confirms ageing 
of the haematopoietic system. Interestingly, platelet counts are normalised in old 
mice lacking both β2 and β3-ARs (double knockout, DKO) (Fig. 19L). Other 
peripheral blood parameters remained unchanged (Fig. 19M-P), suggesting that 
β-adrenergic signals might specifically regulate the megakaryocytic lineage. To 
examine BM Mks, immunofluorescence staining of CD41+CD42+ cells was 
performed. The numbers of CD41+CD42+ cells are significantly increased in old 
WT mice (compared to young WT mice), but are restored in old DKO mice (Fig. 
19A-D and I). Old Mks undergo drastic morphological changes, with increased 
formation of proplatelet-like protrusions or cytoplasmic fragmentations. These 
features, correlated with increased apposition of Mks to the sinusoids, indicate 
promoted thrombopoiesis in aged BM (Fig. 19A-D). However, Mks in old DKO 
mice neither shows similar extent of proplatelet formation (PPF) (Fig. 19J), nor 
abnormal physical contact with sinusoids (Fig. 19E-H and K), suggesting that 
increased thrombopoiesis (a feature of old WT mice) is mitigated in old DKO 
mice. Undifferentiated myeloid/megakaryocyte progenitors originally sit near the 
endosteal surface, moving to central marrow as they differentiate and mature. To 
investigate Mk differentiation at the early progenitor level, BM cells from 
endosteal and non-endosteal fractions were isolated, respectively, and subjected 
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to flow cytometry analysis. In both fractions, the frequency of CD41+ cells within 
the LSK population is increased by 5-fold in old WT mice. In contrast to old WT 
mice, however, the frequency of CD41+ cells is much lower in old DKO mice, 
manifest in the endosteal BM (Fig. 19Q-S). Similarly, the numbers of CD41+ckit+ 
myeloid/megakaryocyte progenitors are doubled in the endosteal regions in old 
WT mice, but normalised in old DKO mice (Fig. 19T-X).  Altogether, the results 
indicate that lack of β-adrenergic signalling in the BM affects megakaryopoiesis 
during ageing.   
























































endosteal (e) non-endosteal (n-e) 
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Figure 19. β-adrenergic signals regulate megakaryopoiesis during ageing.  
(A–D) Representative immunofluorescence staining for CD41 (red) and CD42 
(green) in femoral BM sections of young (A) or old (B) WT mice and young (C) 
or old (D) Adrb2-/-Adrb3-/- (double knockout [DKO]) mice. Arrowheads depict 
megakaryocytes with protrusions (CD41+ CD42+ cells with cell body 
extensions). Scale bar, 250 mm. (I and J) Number of CD41+CD42+ 
megakaryocytes (I) forming protrusions (J) per BM area (n = 4 young WT; n = 5 
young DKO; n = 3 old mice). (E–H) Representative immunofluorescence staining 
for CD41 (red) and EMCN (green) in femoral BM sections of young (E) or old 
(F) WT mice and young (G) or old (H) DKO mice, depicting CD41+ 
megakaryocytes adjacent (arrowheads) or nonadjacent (asterisks) to EMCN+ 
vasculature. Scale bar, 100 mm. (K) Frequency of CD41+ cells in contact with 
EMCN+ vasculature (n = 4 young WT; n = 4 young DKO; n = 4 old WT; n = 3 
old DKO). (L) Circulating platelets in young (n = 11) and old (n = 6) WT mice, 
compared with young (n = 9) and old (n = 5) DKO mice. (M) Circulating 
erythrocytes. (N-P) Frequencies of (N) monocytes, (O) granulocytes and (P) 
lymphocytes among white blood cells. (Q-S) Representative flow chart (Q) and 
quantification of the frequency of CD41+ myeloid or megakaryocyte progenitors 
within lin-sca-1+c-kit+ (LSK) cells in endosteal BM (R) or non-endosteal BM (S) 
from young WT mice (n = 7),  young DKO mice (n = 7), old WT mice (n = 5), 
and old DKO mice (n = 4). (T-W) Representative immunofluorescence staining 
for CD41 (red) and ckit (green) in femoral BM sections of WT or β2-β3-AR DKO 
mice of different age. Images were taken from the diaphysis regions; c-
kit+CD41+ cells are depicted with white arrows. (X) c-kit+CD41+ cells per mm2 
(n = 4 young mice; n = 3 old mice) in endosteal (e) or non-endosteal (n-e) BM 
areas. Regions within 1/5 marrow width from the bone surface are defined as 
endosteal (both sides of the bone), while the remaining 3/5 marrow width in the 
central part are considered as non-endosteal.  Young mice were analysed between 
8–30 weeks of age, and old mice were 66–120 weeks old. Data are means ± SEM. 
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4.3 β2-AR and β3-AR have opposite, stage-divergent and 
stromal cell-dependent effects on Mk differentiation 
β2-AR is widely expressed by many BM cells, including haematopoietic and non-
haematopoietic cells. The expression of β3-AR is generally low/absent in 
hematopoietic cells and is rather restricted to the microenvironment. It has been 
reported that HSPC mobilisation is rhythmically controlled by the two receptors 
in different ways: β2-AR induces clock gene expression whereas β3-AR 
downregulates CXCL12 expressed by MSCs (Mendez-Ferrer et al., 2010). To 
understand how β2/3 adrenergic signalling regulates Mk differentiation, and 
whether the regulation is haematopoietic cell-autonomous or stromal cell-
dependent, a coculture system was established by using HPC-7 cells (murine 
HSC-like cell line) and MS-5 stromal cells (murine mesenchymal cell line) (see 
3.5.1). HPC-7 cells were cultured with or without MS-5 cell layers, in medium 
containing TPO together with selective β2-AR, β3-AR agonists or vehicle 
controls for 4 days (Fig. 20B). HPC-7 cells were categorized into three 
populations based on the expression of cell surface markers, c-kit and CD41: 
population I, c-kithighCD41low undifferentiated progenitor; population II, c-
kitlowCD41low intermediate progenitor; population III, CD41high committed Mk 
progenitor (Fig. 20A). Upon TPO induction, HPC-7 cells follow two Mk 
differentiation routes: gradual transition from population I to II to III, or direct 
commitment from population I to III.  In coculture with MS-5 stromal cells, β3-
AR agonist significantly increases population I at day 2, but reduces population 
III at day 4. In contrast, β2-AR agonist expands population III at day 4 (Fig. 20D). 
Neither β2-AR nor β3-AR agonist affects HPC-7 differentiation in the absence of 
MS-5 stromal cells (Fig. 20C). These results suggest that β2-AR and β3-AR have 
opposite, stage-divergent and stromal dependent effects on Mk differentiation.        
 
















Figure 20. β2-AR and β3-AR have opposite, stage-divergent and stroma-
dependent effects on Mk differentiation. 
 (A) Representative flow cytometry diagram of HPC-7 cells before treatment with 
cytokines (day 0). Scheme showing the cell populations indicating progressive 
megakaryocyte commitment: I, ckithiCD41lo cells; II, ckitloCD41lo cells; III, 
CD41hi cells. Megakaryocyte differentiation trajectory flows from populations I 
to II to III, or I to III. (B) Scheme showing the experimental design. HPC-7 cells 
were cultured alone or co-cultured with MS-5 stromal cells in megakaryocyte 
differentiation medium. (C-D) Quantification of cell populations I, II and III after 
2 or 4 days of treatment with vehicle, β2-AR agonist or β3-AR agonist in (C) 
monoculture or (D) coculture with MS-5 stromal layers (n = 4). Data are means 
± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001. (A, B, E-I) One-way ANOVA 
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4.4 Lack of β2-AR signalling in the microenvironment 
impairs Mk differentiation 
Previous coculture experiments indicate that β2-AR indirectly promotes Mk 
differentiation through stromal cells. To validate the results, MS-5 stromal cells 
were cocultured with human cord-blood derived CD34+ HSPCs in Mk 
differentiation medium, supplemented with or without β2-AR agonist for 10 days 
(see 3.5.2) (Fig. 21A). Immunofluorescence staining with human CD61 antibody 
demonstrates a significant increase of human megakaryocytic cells in β2-AR 
agonist treatment (Fig. 21B-D). To extend these observations to the context of 
ageing, a coculture system was established by using primary haematopoietic cells 
and stromal cells from mice of different ages (see 3.5.3). BM stromal cells were 
isolated from young or old mice. Lineage negative (Lin-) haematopoietic 
progenitors were purified from young double-transgenic mice expressing DsRed 
under the control of the chicken β actin promoter and eGFP under the control of 
von Willebrand factor (Vwf) promoter (DsRed;Vwf-eGFP mice). TPO and the 
β2-AR agonist were given to the coculture for 4 days, in which differentiated 
megakaryocytic cells express both DsRed and eGFP, while undifferentiated 
haematopoietic progenitors only express DsRed (Fig. 21E). The frequency of 
DsRed+eGFP+ cells is tripled in coculture with old stromal cells compared to 
young stromal cells, suggesting ageing from the microenvironment promotes Mk 
differentiation. Consistent with the previous results, the presence of β2-AR 
agonist further increases Mk differentiation, in both young and old stromal cell 
settings (Fig. 21F). These results confirm a universal (independent of age), 
stromal cell-dependent and enhancing effect on Mk differentiation by β2-AR.  
 
  58  
 
Given that the activation of β2-AR increases Mk differentiation in vitro, it is 
speculated that a mirror effect could be obtained from in vivo β2-AR depletion. 
To address the question, young and old mice deficient with β2-AR (but not β3-
AR) were studied. Whereas there is no difference in peripheral platelet counts 
between WT and β2-AR deficient mice in adulthood, old β2-AR deficient mice 
do not increase platelet counts (Fig. 21G). To further investigate the effect of β2-
AR on megakaryopoiesis in different BM niches, BM cells from endosteal and 
non-endosteal fractions were isolated, respectively, and subjected to flow 
cytometry analysis. The frequency of CD41+ LSK cells (same analysis as 
described in 4.2) is significantly decreased in young β2-AR deficient mice, and 
the reduction persists until ageing (Fig. 21H and I), which is in line with the 
observations in DKO mice (Fig.19Q-S).  Similarly, MkPs are decreased in both 
young and old β2-AR deficient mice, compared to their age-matched WT controls 
(Fig. 21J and K). To test whether the effect on megakaryocytic cells (CD41+ LSK 
cells and MkPs) is mediated through the microenvironment, reverse chimera 
experiments were performed, in which lethally irradiated WT or β2-AR deficient 
mice were transplanted with WT or β2-AR deficient BM cells (see 3.2.1). 4 
months after transplantation, β2-AR deficient mice carrying WT BM cells 
recapitulate the endosteal-specific reduction of megakaryocytic cells in primary 
mice (Fig. 21H’’, I’’, J’’ and K’’), while WT recipients with β2-AR deficient BM 
cells do not reproduce the phenotype (Fig. 21H’, I’, J’ and K’). It is notable that 
in non-endosteal BM, both chimeras and primary mice also show a tendency (but 
not statistically different) toward reduced megakaryocytic cells. These results 
suggest that β2-AR has a niche-dependent effect on megakaryopoiesis near 
endosteum, while present certain HSC-autonomous effect in the central marrow.      
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Figure 21. β2-AR signalling in endosteal BM is essential for Mk 
differentiation during ageing. 
(A) Scheme of human umbilical-cord-blood derived CD34+ HSPCs cocultured 
with MS-5 stromal cells. (B–D) Representative immunofluorescence (B and C) 
and number (D) of CD61+ (red) human megakaryocytes in cocultures treated 
with (B) vehicle or (C) β2-AR agonist (clenbuterol, 10 mM) for 10 days (n = 3). 
Scale bar, 250 mm. (C’) Inset of (C). (E) Scheme of Lin- cells derived from Vwf-
eGFP; DsRed mice cocultured with bone marrow stromal cells (BMSCs) from 
young or old mice. (F) Frequency of Vwf-eGFP+ cells in DsRed+ cells in 
cocultures treated with vehicle or β2-AR agonist (clenbuterol, 10 mM) for 4 days 
(n = 3). (G) Circulating platelets in young WT (n = 11), young Adrb2-/- (n = 3), 
or old Adrb2-/- (n = 3) mice. (H-K’’) Frequency of (H-I’’) CD41+ myeloid or 
megakaryocyte progenitors within lin-sca-1+c-kit+ (LSK) cells or (J-K’’) 
CD150+CD41+ megakaryocyte progenitors (MkPs) within lin-c-kit+ (LK) cells 
in endosteal BM (H, H’, H’’, J, J’, J’’) or non-endosteal BM (I, I’, I’’, K, K’, K’’) 
of the following mice: (H, I, J, K) young WT (H, I, n = 6; J, K, n = 3), young 
Adrb2-/- (H, I, n = 6; J, K, n = 8) or old Adrb2-/- (n = 4) mice; (H’, I’, J’, K’) 
lethally irradiated WT recipients of WT (n = 5) or Adrb2-/- (n = 4) BM cells; (H’’, 
I’’, J’’, K’’) lethally irradiated WT (n = 5) or Adrb2-/- (n = 4) recipients of WT 
BM cells. Data are means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. (D, H’, 
H’’, I’, I’’, J’, J’’, K’, K’’) Unpaired two-tailed t test. (F, G, H, I, J, K) one-way 
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4.5 β2-AR promotes Mk differentiation through MSC-
derived IL-6 
To get mechanistic insight of β2-AR-dependent megakaryopoiesis, multiple 
ELISA screening of pro-inflammatory cytokines involved in ageing and Mk 
differentiation was performed. Extracellular fluids extracted from young murine 
endosteal or non-endosteal BM fractions were subjected to analysis. IL-6 and 
IFNγ levels are generally higher in endosteal BM than non-endosteal BM, and 
both cytokines are downregulated specifically in endosteal BM of β2-AR 
deficient mice (Fig. 22A and B). IL-6 levels are also significantly increased in the 
ageing BM (Fig. 18B and G), suggesting that IL6 might be downstream of β2-
AR in endosteal niches. MS-5 stromal cells were treated with the selective β2-
AR agonist, which demonstrates that IL6 mRNA transcripts are doubled in 
response to β2-AR activation. Yet the increase is abrogated when protein kinase 
A (PKA), a secondary effector to transduce β2-AR signalling, is 
pharmacologically inhibited (Fig. 22C). To strengthen the connection between 
β2-AR and IL-6 in vivo, an IL-6 deficient mouse model (see 3.1) was studied. It 
has been reported that these mice are protected from the decrease of circulating 
lymphocytes with age. Moreover, old IL-6 deficient mice develop less severe 
anaemia, whereas their platelet counts are slightly lower than their WT 
counterparts (McCranor et al., 2013). Immunofluorescence staining of BM 
CD41+CD42+ cells demonstrates that both β2-AR and IL-6 deficient mice (in 
adulthood) display significantly fewer Mks compared to WT controls (Fig. 22D-
G). To test whether β2-AR locally regulates Mk differentiation through IL-6 in 
the BM, a long-term primary culture system was established to mimic murine BM 
microenvironment ex vivo. Total BM cells from WT or IL-6 deficient mice were 
grown in myeloid-culture medium for 2-3 weeks until stromal cell layers were 
formed and haematopoietic cells were grown. After the primary culture was 
  62  
 
developed, TPO was given for extra 4 days to induce Mk differentiation, during 
which the β2-AR agonist or vehicle control were added to the culture (Fig. 22H). 
The number of CD41+LSK cells is significantly increased in response to β2-AR 
in WT BM culture. However, activation of β2-AR fails to increase CD41+LSK 
cells in IL-6 deficient BM culture (Fig. 22I).  Taken together, these results suggest 
that β2-AR in endosteal niches promotes Mk differentiation through stromal cell-
derived IL-6.                  



















Figure 22. β2-AR promotes Mk differentiation through stromal cell-
derived IL-6. 
(A-B) Concentration of (A) IFNγ and (B) IL-6 in endosteal (e) or non-endosteal 
(n-e) BM supernatant from adult WT (n = 6), Adrb2-/- (n = 4), or Adrb3-/- (n = 7) 
mice. (C) Il6 mRNA expression (fold change) in MS-5 stromal cells treated with 
β2-AR agonist (clenbuterol, 10 mM), PKA inhibitor (H-89, 5 mM), or vehicle for 
2 days (n = 3). (D–G) Representative immunofluorescence (D–F) and 
quantification (G) of CD41+ (red) CD42+ (green) megakaryocytes (yellow) in 
adult WT (n = 5), Adrb2-/- (n = 3), or Il6-/- (IL6 KO) (n = 5) mice. Scale bar, 250 
mm. (H) Scheme of long-term BM culture from WT or Il6-/- mice. (I) Myeloid or 
megakaryocyte progenitors (CD41+ LSK cells) in primary BM culture from WT 
or Il6-/- mice treated with β2-AR agonist (clenbuterol, 10 mM) or vehicle for 4 
days (n = 4). Data are means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. One-
way ANOVA followed by Bonferroni pairwise comparisons. 
β2-AR ag. 
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4.6 Lack of β3-AR signalling in the microenvironment 
impacts HSC lineage bias 
The cell line experiments indicate that β3-AR has an opposite effect on the size 
of CD41+ cells. Activation of β3-AR decreases megakaryocytic cells possibly 
through preventing Mk differentiation from HSCs. However, in the primary 
culture systems (lin- cells cultured with young/old stromal cells, or hCD34+ 
HSPCs cultured with MS-5 cells), terminal Mk differentiation appears to be 
unaffected by β3-AR agonist (data not shown). A recent paper reported that adult 
β3-AR deficient mice exhibit myeloid-bias in the circulation, paralleled with 
reduced lymphoid multipotent progenitors (LMPP) in the BM.  It is therefore 
hypothesized that β3-AR does not directly regulate Mk differentiation, but 
controls the switch of myelopoiesis/lymphopoiesis at the early stem and 
progenitor cell level. To test the hypothesis, young and old mice deficient with 
β3-AR (but not β2-AR) were studied. BM cells from endosteal and non-endosteal 
fractions were isolated, and the frequency of different HSC populations (LT-
HSCs, myeloid-biased HSC and lymphoid-biased HSCs) was analysed by flow 
cytometry (Fig. 23A). Upon ageing, LT-HSCs and myeloid-biased HSCs are 
expanded while lymphoid-biased HSCs are reduced in WT BM (both endosteal 
and non-endosteal fractions), an evidence of myeloid skewing. Interestingly, 
lymphoid-biased HSCs are lowered by one-third, specifically in endosteal BM of 
adult β3-AR deficient mice, to a similar extent of old WT mice. Old β3-AR 
deficient mice do not aggravate the loss of lymphoid-biased HSCs (Fig. 23B, C, 
D, E, F and G). To test whether the effect is mediated through the 
microenvironment, lethally irradiated WT or β3-AR deficient mice were 
transplanted with WT or β3-AR deficient BM cells (see 3.2.1). The reverse 
chimera experiments confirm that the regulation of β3-AR is niche-dependent, 
since lymphoid-biased HSCs are not attenuated in WT recipients carrying β3-AR 
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deficient BM cells (Fig. 23B’, B’’, C’, C’’, D’, D’’, E’, E’’, F’, F’’, G’ and G’’). 
Based on the phenotype in lineage-biased HSCs, the corresponding 
haematopoietic progenies (mature myeloid or lymphoid cells) in the BM was 
further investigated. Despite the differences being nonsignificant, adult β3-AR 
deficient mice exhibit a tendency toward increased frequency of granulocytes 
(Ly-6G+CD11b+ cells) but decreased B lymphocytes, manifest in non-endosteal 
BM. Compared to old WT mice, old β3-AR deficient mice show similar reduction 
of B lymphocytes (Fig. 23H-K). However, β3-AR deficient mice (compared to 
their age-matched WT controls) do not show clear differences in circulating 
myeloid or lymphoid cells (Fig. 23L and M). Interestingly, impaired lymphoid-
biased HSCs near endosteum correlates with increased concentration of IL-1α 
and IL-1β (Fig. 23N and O), which have been reported to enhance 
myeloid/megakaryocytic differentiation or suppress lymphopoiesis. These results 
suggest that lack of β3-AR in endosteal niches majorly impairs lymphoid-biased 
HSCs, which might accelerate skewed myeloid differentiation upon ageing.  
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Figure 23. Lack of β3-AR in endosteal BM impairs lymphoid-biased HSCs. 
(A) Representative flow cytometry diagram of HSC populations based on CD41 
and CD150 expression. (B-G’’) Frequency of (B-C’’) CD150lo/-CD41- lymphoid-
biased HSCs, (D-E’’) CD150+CD41+ myeloid-biased HSCs or (F-G) 
CD150+CD41- LT-HSCs in (B, D, F) endosteal or (C, E, G) non-endosteal BM 
CD34-LSK cells from the following mice: (B, C, D, E, F, G) young WT (n = 7), 
young Adrb3-/- (n = 7) or old Adrb3-/- (n = 5) mice; (B’, C’, D’, E’, F’,G’) lethally-
irradiated WT recipients of WT (n = 5) or Adrb3-/- (n = 5) BM cells; (B’’, C’’, 
D’’, E’’, F’’, G’’) lethally-irradiated WT (n = 4) or Adrb3-/- (n = 3) recipients of 
WT BM cells. (H-K) Frequency of (H, I) Ly6G+CD11b+ granulocytes or (J, K) 
B220+ lymphocytes in (H, J) endosteal or (I, K) non-endosteal BM CD45+ cells 
from young WT (n = 3), young Adrb3-/- (n = 4) or old Adrb3-/- (n = 5) mic. (L-M) 
Frequency of (L) granulocytes and (M) lymphocytes in white blood cells (WBCs) 
in young WT (n = 10), young Adrb3-/- (n = 4) or old Adrb3-/- (n = 6) mice. Data 
are means ± SEM. (N-O) Concentration of (N) IL-1α and (O) IL-1β in endosteal 
(e) or nonendosteal (n-e) BM extracellular fluid (BMECF) from adult WT mice 
(n = 6), Adrb2-/- mice (n = 4), or Adrb3-/- mice (n = 7). (B’, C’, D’, E’, F’, G’, B’’, 
C’’, D’’, E’’, F’’, G’’) Unpaired two-tailed t test. (B, C, D, E, F, G, H-O) One-
way ANOVA and Bonferroni pairwise comparisons. 
endosteal (e) endosteal (e) non-endosteal (n-e) non-endosteal (n-e) 
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4.7 β3-AR signalling regulates lymphoid-biased HSCs 
partially through Nos1-dependent pathway 
The precise mechanisms by which β3-AR balances myeloid/lymphoid output 
have yet to be elucidated. Whereas all β-ARs transduce signals through activating 
G-proteins, it has been reported that NO is a second messenger restricted to β3-
AR activation (Gauthier et al., 1998). A recent publication indicates that NO 
synthesis pathways bridge ageing of the microenvironment and HSCs (Hennrich 
et al., 2018). Dr. Monika Wittner and Dr. Fawzia Louache (collaborators of the 
lab) discovered that NO synthase 1 (Nos1) deficient mice exhibit increased 
platelet/granulocytes but decreased B lymphocytes in the circulation (Ho et al., 
2019). Supporting the observation on peripheral myeloid-skewing differentiation, 
immunofluorescence staining of CD41 and c-kit demonstrates that adult Nos1 
deficient mice expand myeloid/megakaryocytic progenitors (CD41+ckit+ cells), 
specifically near endosteal BM (Fig. 24A, C and D). Consistently, adult β3-AR 
deficient mice exhibit increased BM myeloid/megakaryocytic progenitors near 
endosteum (Figure 24A, B and D), despite terminal differentiated cells being 
unchanged in the circulation (Fig. 23L). These lines of evidence suggest that β3-
AR in endosteal niches might regulate lymphoid-biased HSCs through Nos1-
dependent NO generation, leading to an expansion of myeloid progenitors in the 
BM. In WT mice, NO concentration is remarkably higher in endosteal BM 
compared to non-endosteal BM (Fig. 24H). This can be explained by twice the 
difference of Nos1 (but not Nos2 or Nos3) mRNA transcripts in the two niches 
(Fig. 24E). Interestingly, NO concentration and Nos1 mRNA are significantly 
reduced in endosteal BM of β3-AR deficient mice (Fig. 24E-H). To study the 
functional role of Nos1 in β3-AR-dependent haematopoiesis, the aforementioned 
primary culture system was performed. In this regard, BM cells were obtained 
from Vwf-eGFP mice, which allows to stringently distinguish platelet/myeloid-
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biased HSCs from lymphoid-biased HSCs by eGFP (Fig. 24I). Selective β3-AR 
agonist and/or Nos1 inhibitor were added to the culture during TPO induction. 
Pharmacological activation of β3-AR expands the number of Vwf-eGFP- 
(lymphoid-biased) HSCs, while Vwf-eGFP+ (platelet/myeloid-biased) HSCs are 
unaffected. Nos1 inhibition abrogates the enhancing effect of β3-AR agonist on 
lymphoid-biased HSCs (Fig. 24J and K), confirming that β3-AR regulates 






















Figure 24. β3-AR regulates lymphoid-biased HSCs through Nos-1-
dependent pathway.  
(A–D) Representative immunofluorescence (A–C) and quantification (D) of c-
kit+ (green) CD41+ (red) myeloid or megakaryocyte progenitors (arrowheads) in 
endosteal BM of WT (n = 10), Adrb3-/- (n = 8), or Nos1-/- (n = 4) mice. Endosteal 
BM is considered as regions within one-fifth marrow width from the bone surface. 
Scale bar, 300 mm. (E-G) mRNA levels (fold) of (E) Nos1 (F) Nos2 and (G) 
Nos3 in the endosteal (e) or non-endosteal (n-e) BM of adult WT mice (n = 6) 
and β3-AR KO mice (n = 7). (H) Nitrate concentration in BM extracellular fluid 
(BMECF) of young WT (n = 6) or Adrb3-/- (n = 7) mice.  (I) Scheme of long-term 
BM culture from Vwf-eGFP mice. (J-K) Number of (J) lin-sca-1+c-kit+CD34-
CD48-CD150+Vwf-eGFP- lymphoid-biased HSCs or (K) lin-sca-1+c-kit+CD34-
CD48-CD150+Vwf-eGFP+ platelet/myeloid-biased HSCs in primary BM culture 
from Vwf-eGFP mice treated with β3-AR agonist (BRL37344, 10 mM), Nos1 
inhibitor (L-VINO, 100 mM), or vehicle for 4 days (n = 8). Data are means ± 
SEM. *p < 0.05; **p < 0.01; ***p < 0.001. One-way ANOVA and Bonferroni 
pairwise comparisons. AR: adrenergic receptor. 
* 
** 
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4.8 Lack of β3-AR-Nos1 signalling accelerates 
haematopoietic ageing by remodelling HSC-supporting 
niches 
The previous results suggest that impaired β3-AR-Nos1 signalling accelerates 
ageing of the haematopoietic system (mainly expansion of 
myeloid/megakaryocytic progenitors) by promoting lymphoid deficiency at the 
level of HSCs. Given the regulation is not HSC cell-autonomous, whether adult 
β3-AR and Nos1 deficient mice display age-related BM niche remodelling was 
further tested. It has been reported that the overall BM vessel density is increased 
in aged mice. However, endosteal vascular niches contract while non-endosteal 
vascular niches expand (Ho et al., 2019). Whole-mount confocal imaging of thick 
femur sections was performed in order to study endothelial architecture at a 3D-
resolution level. Immunofluorescence staining of CD31 and EMCN reveals that 
TZVs, specialized endosteal vessels that connect arterioles and sinusoids, are 
decreased in β3-AR and Nos1 deficient mice (Fig. 25E-H). In contrast, small 
capillaries are expanded in central marrow (Fig. 25I). Mks tightly control HSC 
quiescence and proliferation under homeostasis. A drastic remodelling of Mk 
niches is found in aged mice, characterised by Mk increasing PPF, being closer 
to sinusoids but distant from HSCs (Maryanovich et al., 2019). To examine Mks 
and their interaction with sinusoids, immunofluorescence staining of CD41 and 
EMCN was performed. Adult β3-AR and Nos1 deficient mice show higher 
frequency of Mks (CD41+ cells) adjacent with sinusoids (EMCN+ cells) 
compared to age-matched WT controls (Fig. 25A-D). Immunofluorescence 
staining of BM CD150+lin-CD48- HSCs and CD42+ Mks uncovers that HSCs 
redistribute away from Mks in β3-AR deficient BM, to a similar extent as 
normally aged BM (Fig. 25J-M). These results together suggest that lack of β3-
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AR-Nos1 signalling alters Mk and vascular niches, which correlates with HSCs 
apposition to Mks.     
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Figure 25. Deficient β3-AR accelerates BM niche ageing.  
(A–D) Representative immunofluorescence (A-C) and quantification (D) of 
CD41+ (red) megakaryocytes adjacent (arrowheads) or nonadjacent (asterisks) to 
EMCN+ (green) BM vasculature of WT (n = 9), Adrb3-/- (n = 6), or Nos1-/- (n = 
4) mice. Scale bar, 250 mm. (E–G) Representative whole-mount 
immunofluorescence of CD31 (green) and EMCN (red) in WT (n = 7), Adrb3-/- 
(n = 5), or Nos1-/- (n = 4) BM. Arrowheads in insets (E’), (F’), and (G’) depict 
CD31hiEMCN- capillaries. (H, I) Quantification of (H) CD31hiEMCNhi transition 
zone vessels and (I) CD31hiEMCN- capillaries with <6 mm diameter. Scale bar, 
250 mm. (J-M) Representative immunofluorescence (J-L) and distribution (M) of 
BM CD150+ (red) HSCs (negative for mature haematopoietic lineage markers, 
blue) adjacent (asterisks) or nonadjacent (arrows) to CD42+ (green) 
megakaryocytes in femoral BM sections of young WT mice (n = 3), adult Adrb3-
/- mice (n = 5) and old WT mice (n = 3). Scale bar, 50 μm. Data are means ± SEM. 
* p < 0.05; ** p < 0.01; *** p < 0.001. (D, H, I) One-way ANOVA and Bonferroni 
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4.9 BM niche remodelling in LmnaG609G/G609G progeria 
mouse model 
It has been reported that HGPS recapitulates certain hallmarks of haematopoietic 
ageing. Using the LmnaG609G/G609G mouse model of HGPS, increased platelet 
counts and myeloid-biased differentiation in circulation were observed (Ho et al., 
2019). Importantly, these features appeared to be driven by the microenvironment, 
since chimera mice with LmnaG609G/G609G donor BM cells did not reproduce the 
phenotype. Analysis of BM histology of progeroid mice reveals that Th+ nerve 
fibres are not expanded. Vessel dilation is present in progeroid BM, while 
reduced TZVs and increased small capillaries (vascular remodelling in normal 
ageing) are not observed. However, progeroid mice suffer the same Mk niche 
remodelling found in normal ageing: Mk being closer to sinusoids (Fig. 26A-C) 
with increasing PPF (Fig. 26D-F). Moreover, age-related pro-inflammatory 
cytokines are augmented in progeroid BM (Fig. 26G-K). These results highlight 
the differences (vasculature and nerve fibres) between normal and pathological 
conditions, but also suggest that similar microenvironmental alterations (Mk 
niche remodelling and increased inflammatory cytokines) contribute to premature 


























Figure 26. Premature haematopoietic ageing in HGPS concurs with BM Mk 
niche remodelling and inflammation.  
(A, B) Representative immunofluorescence staining for CD41 (red) and EMCN 
(green) in femoral BM sections of adult WT (Lmna+/+; n = 3) and LmnaG609G/G609G 
(n = 4) mice. White stars, CD41+ cells nonadjacent to EMCN+ vasculature; White 
arrows, CD41+ cells adjacent to EMCN+ vasculature. Scale bar, 100 μm. (C) 
Frequency of CD41+ cells in contact with EMCN+ vasculature. (D, E) 
Representative immunofluorescence staining for CD41 (red) and CD42 (green) 
in femoral BM sections of adult WT (Lmna+/+; n = 3) and LmnaG609G/G609G (n = 4) 
mice. Scale bar, 250 μm. (F) CD41+CD42+ megakaryocytes with protrusions 
(clear cell body extensions, depicted by white arrows in E) per BM area. (G–K) 
Concentration of (G) IL-1β, (H) IL-6, (I) IL-1α, (J) IL-3, and (K) IFNγ in the BM 
extracellular fluid (BMECF) of adult WT (Lmna+/+; n = 9) and LmnaG609G/G609G 
(n = 9) male mice. Data are means ± SEM. *p < 0.05; **p < 0.01 (unpaired two-
tailed t test). 
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4.10 Chronic β3-AR agonist treatment partially rejuvenates 
haematopoietic ageing in HGPS 
Previous results suggest that β3-AR deficient mice and progeroid mice exhibit 
similar microenvironmental alterations found in normal ageing. Additionally, a 
recent publication reported that chronic treatment of β3-AR agonist can 
rejuvenate old HSCs (Maryanovich et al., 2019). Therefore, whether 
pharmacological targeting β3-AR can also improve pathological haematopoietic 
ageing in HGPS was tested. LmnaG609G/G609G mice were daily injected with the 
selective β3-AR agonist for over 2 months (experiment carried out by our 
collaborator Cristina Gonzalez). Mice were sacrificed at the end of the treatment 
for histology and flow cytometry analysis. Circulating granulocytes are decreased, 
while lymphocytes are increased in response to chronic β3-AR activation (Fig. 
27A and B). Consistently, expansion of BM granulocytes and B-lymphoid 
deficiency are rescued (Figure 27C and D). The normalisation of myeloid-biased 
differentiation correlates with altered HSC composition, in that high frequency 
of LT-HSCs are reduced while impaired lymphoid-biased HSCs are restored (Fig. 
27E-H). Given that progeroid mice appear to follow the same Mk remodelling 
signature, it is hypothesized that rejuvenation of progeroid HSCs under β3-AR 
activation is mainly due to restored HSC-Mk interaction. To test the hypothesis, 
immunofluorescence staining of HSCs (CD150+lin-CD48- cells), haematopoietic 
progenitors (c-kit+ cells) and Mks (CD42+ cells or CD41+ cells) was performed. 
Similar to β3-AR deficient mice and normally aged mice, HSCs locate more 
distantly from Mks in HGPS. However, this alienation is partially restored by β3-
AR agonist treatment (Fig. 27L-N and P). Likewise, lower frequency of progeroid 
Mks (CD41+ cells) are found adjacent with haematopoietic progenitors (c-kit+ 
cells), but this association is normalised in response to chronic β3-AR activation 
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(Fig. 27I-K and O). These results suggest that activating β3-AR can improve 
certain haematopoietic and niche ageing features in HGPS.      




























non-endosteal (n-e) non-endosteal (n-e) endosteal (e) endosteal (e) 
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Figure 27. β3-AR agonist improves HSC number, lineage skewing and 
localization near Mks in HGPS. 
(A and B) Frequency of (A) granulocytes and (B) lymphocytes in white blood 
cells (WBCs) of WT mice (n = 8) or LmnaG609G/G609G mice (n = 6) treated with 
β3-AR agonist (BRL37344, 2 mg/kg/day, intraperitoneally [i.p.]) or vehicle for 8 
weeks. (C, D) Frequency of BM (C) Ly6G+CD11b+ neutrophils or (D) B220+ B 
cells in these mice. (E-H) Frequency of (E, F) LT-HSCs and (G, H) lymphoid-
biased HSCs in CD34-LSK cells in (E, G) endosteal or (F, H) non-endosteal BM 
of these mice (n = 6). (I–K, O) Representative immunofluorescence (I–K) and 
quantification (O) of CD41+ megakaryocytes adjacent (asterisks) or nonadjacent 
(arrowheads) to c-kit+ (green) HSPCs in BM of WT mice (n = 3) and 
LmnaG609G/G609G mice (n = 5) treated with β3-AR agonist or vehicle. Scale bar, 50 
mm. (L–N, P) Representative immunofluorescence (L–N) and distribution (P) of 
BM CD150+ (red) HSCs (negative for mature haematopoietic lineage markers, 
blue) adjacent (asterisks), or nonadjacent (arrows) to CD42+ (green) 
megakaryocytes. Scale bar, 50 mm. Data are means ± SEM. *p < 0.05; **p < 
0.01; ***p < 0.001. (A–H, O) One-way ANOVA and Bonferroni pairwise 
comparisons. (P) Two-way ANOVA and Bonferroni pairwise comparisons. 
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4.11 Chronic β3-AR agonist treatment improves 
exacerbated megakaryopoiesis in MPNs 
Since modulating sympathetic signalling was able to reverse myeloid-skewing in 
premature ageing, whether it can also be applied to the treatment of age-related 
blood disorders was tested. MPNs share several haematopoietic features with 
normal ageing, such as BM inflammation, increased HSC proliferation and 
myeloid-biased differentiation toward platelet production. A previous study by 
our group reported that the development of MPNs is accelerated in β3-AR 
deficient microenvironment. Chronic treatment of β3-AR agonist or 
neuroprotective agents mitigates disease progression by lowering peripheral 
platelet/neutrophil counts and improving myelofibrosis (Arranz et al., 2014). BM 
histology from the same cohort of experiments (MPN mice treated with β3-AR 
agonist and β3-AR deficient mice carrying MPN BM cells) was analysed in order 
to get insight into the biology of Mks. H&E staining shows a significant reduction 
of Mk numbers in β3-AR agonist-treated MPN mice (Fig. 28A and B). Atypical 
Mk clusters and aberrant Mk distribution, a hallmark of myelofibrosis, are also 
normalised (Fig. 28A-C). Immunofluorescence staining of CD41 and CD42 cells 
was performed, confirming that both Mk precursors (small CD41+CD42+ cells) 
and mature Mks (large CD41+CD42+ cells) are decreased (Fig. 28H-K). In 
contrast, higher number of megakaryocytic cells was observed in β3-AR deficient 
mice with MPN, as compared to WT recipients (Fig. 28D-G). BM trephines of 
MPN patients from a follow-up clinical study led by Dr. Drexler et al. were 
subjected to histology analysis. Immunohistochemistry staining of CD34 (which 
labels HSPCs and vessels) reveals that Mk (identified by cell size)-vessel contact 
is decreased after β3-AR agonist treatment (Fig. 28L-N), despite thrombocytosis 
reportedly being unimproved (Drexler et al., 2019). Taking into consideration the 
relatively low dose and duration of treatment in the human study, these results 
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suggest that chronic β3-AR agonist treatment could potentially improve 
exacerbated megakaryopoiesis in MPNs.  
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Figure 28. β3-AR agonist improves exacerbated megakaryopoiesis in MPNs. 
 (A, B) Representative H&E staining in femoral BM sections of MPN mice (Mx1-
cre;JAK2(V617F)) treated with (A) vehicle (n = 3) or (B) β3-AR agonist (n = 4). 
Scale bar, 250 μm. Megakaryocyte clusters are shown in vehicle treated group. 
Single megakaryocyte (labelled with star) was shown in β3-AR agonist treated 
group. (C) Quantification of megakaryocyte distribution. Endosteal region was 
defined as the area within 1/5 of the BM width from the bone surface. 
Quantification was done by averaging the results from at least 3 random fields 
(10X magnification) per mouse. (D-E) Representative immunofluorescence 
staining for CD41 (red) and CD42 (green) in femoral BM sections of (D) WT 
mouse and (E) β3-AR KO mouse transplanted with Mx1-cre;JAK2(V617F) 
mouse BM cells. Scale bar, 75 µm. (F) CD41+CD42+ cells per BM field (n = 3). 
(G) Small (< 300 μm2) CD41+CD42+ cells (n = 3). (H, I) Representative 
immunofluorescence staining for CD41 (red) and CD42 (green) in femoral BM 
sections of mice treated with (Q) vehicle or (R) β3-AR agonist (BRL37344, 2 mg 
kg-1) for 12 weeks. Scale bar, 75 μm. (J) CD41+CD42+ megakaryocytes per BM 
field (n = 3). (K) Small (< 300 μm2) CD41+CD42+ megakaryocytes (n = 3) per 
BM field. Average of ≥6 random fields. (L-M) Representative 
immunohistochemistry staining for CD34 (brown) in BM trephines from MPN 
patients treated with β3-AR agonist (mirabegron) for 24 weeks. Vessels are 
identified as CD34+ tubular structure while megakaryocytes are identified by 
morphology. Arrowheads depict megakaryocytes adjacent with vessels. Asterisks 
depict megakaryocytes nonadjacent with vessels. Scale bar, 50 μm. (N) 
Quantification of the distance of megakaryocytes to CD34+ vessels. Data are 
means ± SEM * p < 0.05; ** p < 0.01. (C, F, G, J, K) Unpaired two-tailed t test. 
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5. Conclusions and Discussions 
HSC ageing was initially considered to be driven mostly by cell-autonomous 
mechanisms. However, it is important to note that not only HSCs, but all the other 
cell types, suffer biological changes with age. The close relationship between BM 
HSCs and their neighbouring cells suggests that upon ageing, alterations in both 
compartments (HSC and the microenvironment) might have influences on each 
other. Given that most HSCs are maintained in perivascular regions, vessels and 
vessel-adjacent niche populations in response to ageing have been reported by 
many groups. Common findings are that cells near endosteum (transition zone 
vessels, or TZVs, arterioles and their associated MSCs) contract while cells away 
from bone surfaces (Mks, sinusoids, small capillaries and their associated MSCs) 
expand or remain unchanged.  However, studies regarding age-related changes in 
the size of BM sympathetic neurons are controversial, and the mechanisms by 
which sympathetic signalling regulates haematopoietic ageing are largely 
unexplored. Based on the observation that Th+ nerve fibres are augmented in aged 
mice, the current study expands this observation to further dissecting neuronal 
regulation of HSC ageing through the microenvironment, centred on 
myeloid/megakaryocytic-biased differentiation of HSCs.               
 
5.1 Key findings of the study 
The current study demonstrates that increased sympathetic activity causes 
increased myelopoiesis during ageing, majorly through activating β2-AR, since 
high peripheral platelets and BM megakaryocytic cells are present in old WT 
mice but absent in old Adrb2-/- mice (or Adrb2-/-Adrb3-/- mice), but not in old 
Adrb3-/- mice (Fig. 19 and Fig. 21). The effect appears to be dominant in the 
endosteal BM, where the alteration of Mk lineage cells is more prominent, 
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compared to non-endosteal compartments (Fig. 19R and S, and Fig. 21H-K). The 
chimera mouse studies further indicate that the regulation of Mk differentiation 
by β2-AR in endosteal niches is dependent on the microenvironment (Fig. 21H-
K). Supported by in vitro coculture experiments, β2-AR agonist promotes Mk 
differentiation only when stromal cells are present (Fig. 20). TPO is indispensable 
for driving Mk differentiation, while cytokines upregulated in ageing, such as IL-
1, IL-3 and IL-6, have been reported to promote the process. The study confirms 
that IL-6 concentration is higher in old mice, but is reduced in adult β2-AR 
deficient mice and specifically in the endosteal BM (Fig. 22B). MS-5 stromal 
cells increase IL-6 mRNA transcripts under β2-AR activation (Fig. 22C), 
revealing MSC-like cell as one possible source of IL-6 in the endosteal niches. 
Moreover, β2-AR agonist treatment fails to enhance Mk differentiation when IL-
6 is depleted from the microenvironment (Fig. 22I). These results strongly 
suggest that β2-AR in endosteal niches contributes to Mk differentiation during 
ageing, which relies on stromal cell-derived IL-6. However, certain 
haematopoietic cell-autonomous effects on MkPs in non-endosteal niches are also 
observed (Fig. 21I and K), despite the results neither showing significant 
difference nor supported by the coculture experiment. β2-AR is reportedly 
expressed by a wide range of cell types, including both haematopoietic and non-
haematopoietic cells. Therefore, a direct activation of β2-AR on haematopoietic 
progenitors contributing to megakaryopoiesis during ageing in non-endosteal 
niches cannot be excluded. Dr. Chen et al. have reported that α-AR directly 
regulates Mk migration, adhesion and proplatelet formation under stress (Chen et 
al., 2016). Given compensatory mechanisms of α-ARs and β-ARs being reported, 
it is also likely that deficient β2-AR upregulates α-AR to promote Mk maturation. 
Future studies on the coordinating roles of α-ARs and β-ARs in regulating HSC 
ageing are expected and will certainly provide additional value to the field.      
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Interestingly, β3-AR exhibits opposing effects on myelopoiesis compared to β2-
AR. Coculture experiments (HPC-7 cells and MS-5 cells) show that β3-AR 
agonist treatment inhibits Mk differentiation in the presence of stromal cells (Fig. 
20D). The effect seems to be explained by differentiation blockade at the HSC 
level, since terminally differentiated population (CD41hi cells) declines whereas 
the most primitive, uncommitted population (CD41loc-kithi cells) expands. 
Supporting this concept, in the long-term BM primary culture system, the number 
of HSCs, or more specifically the Vwf-eGFP- lymphoid-biased HSCs, is 
significantly increased under β3-AR activation (Fig. 24J). These results suggest 
that β3-AR might suppress myelopoiesis/megakaryopoiesis by preferentially 
activating the lymphoid-primed HSC compartment. Indeed, adult β3-AR 
deficient mice exhibit lower frequency of lymphoid-biased HSCs in endosteal 
BM (Fig. 23B and C), and a tendency toward increased granulocytes at the 
expense of B-cells (Fig. 23H-K). The chimera experiments confirm β3-AR 
signalling acts through the microenvironment (Fig. 23B and C), in line with the 
fact that HSCs do not express β3-AR. The endosteal-specific loss of lymphoid-
biased HSCs correlates with higher concentration of IL-1, which have been 
reported to promote myeloid/megakaryocytic expansion (Beaulieu et al., 2014; 
Nishimura et al., 2015) (Pietras et al., 2016) or inhibit lymphopoiesis (Kennedy 
and Knight, 2015). Mechanistically, Nos-1-dependent NO production is a likely 
downstream pathway. β3-AR deficient mice have lower levels of Nos-1 
transcripts and NO content in endosteal BM (Fig. 24E-H), and pharmacological 
inhibition of Nos-1 abrogates the effect of β3-AR agonist on lymphoid-biased 
HSCs (Fig. 24J). Strikingly, adult Nos-1 deficient mice and β3-AR deficient mice 
both display premature ageing of the BM architecture: diminished TZVs, 
increased numbers of small capillaries, and Mks apposition to sinusoids (Fig. 
25A-I). Contraction of endosteal vessels possibly causes lymphoid deficiency in 
β3-AR deficient mice, since the majority of lymphoid-primed HSPCs is 
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reportedly present near endosteum. Moreover, LT-HSCs are found redistributing 
away from their putative Mk niches in β3-AR deficient mice (Fig. 25J-M). 
Altogether, these results suggest that lack of β3-AR remodels HSC-supporting 
niches into an ageing-permissive microenvironment, which accelerates lymphoid 
deficiency partially through Nos-1-NO dependent pathway.  
 
These findings are consistent with a recent publication by Dr. Maryanovich et al. 
in that certain degree of premature ageing happens in β3-AR deficient mice. 
However, some differences also exist. In their study, imbalanced myeloid-
lymphoid output is evident in BM HSPC compartments and the mature progenies 
in circulation, whereas in the present study only BM HSPCs (but not circulating 
blood cells) display myeloid skewing. In addition, Maryanovich et al claim that 
administration of a β3-AR agonist in old mice rejuvenates overall aged 
haematopoiesis. The present study demonstrates that the same β3-AR agonist can 
restore myeloid/megakaryocytic expansion in a mouse model of MPNs (Arranz 
et al., 2014) (Fig. 28) and progeria syndrome (Fig. 27). However, haematopoietic 
rejuvenation is not observed (evidenced by unchanged peripheral platelet counts) 
in WT mice treated with β3-AR agonist over 40 weeks (data not shown). 
Likewise, old MPN patients treated with β3-AR agonist render normal HSC-Mk 
distribution in the BM (Fig. 28L-N), but do not show rejuvenation in the 
peripheral blood system (Drexler et al., 2019). Furthermore, Dr. Maryanovich et 
al. propose that Th+ fibres are reduced in ageing, aggravating HSC functions in a 
β3-AR-dependent manner. In contrast, investigators from our lab have observed 
increased Th+ fibres in old mice (Ho et al., 2019), consistent with the well-known 
increase in sympathetic activity in the elderly. The present study further reveals 
that sympathetic activation of β2-AR is indispensable for myeloid-bias toward 
platelet production during ageing. These discrepancies suggest that neuronal 
regulation of HSC ageing cannot be attributed to β3-AR signalling alone. Of note, 
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changes of Th+ fibres shown in BM sections does not equal to the levels of 
innervation. Myeloid and lymphoid cells are sources of neurotransmitters 
(Cosentino et al., 2015), meaning that BM neuronal activities incompletely 
depend on the area covered by nerve fibres. Sympathetic regulation of HSC 
myeloid-skewing is more likely explained by the activation or inactivation of 
different adrenergic receptors. A functional switch of neurotransmission (β2-AR 
overriding β3-AR) with age, rather than a general decline of innervation might 
initiate BM niche remodelling and subsequently promote HSC myeloid-skewing 
toward platelet production (Fig. 29).  
 
In contrast to normal physiological ageing, the pathological ageing models show 
opposite phenotype in BM Th+ fibres: either unchanged in progeria (HGPS) (Ho 
et al., 2019) or decreased in age-related myeloid disorders (MPNs) (Arranz et al., 
2014). However, similar BM microenvironment alterations, such as inflammation 
(compare Fig. 18 and Fig. 26G-K) and Mk niche remodelling (compare Fig. 19A-
H an Fig. 26A-F), are shared among normal ageing, pathological ageing, and β3-
AR deficient mice. These results suggest that instead of overstimulating β2-AR, 
inactive β3-AR might play a dominant role in the development of pathological 
ageing. Therefore, this study has tested whether activating β3-AR can rejuvenate 
certain ageing features in progeria and myeloproliferative disorders. In progeroid 
mice, chronic β3-AR agonist treatment normalises imbalanced myeloid/lymphoid 
output (Fig. 27A-D), reduces the frequency of LT-HSCs (Fig. 27E-H) and 
restores the proximal association of HSCs to Mks (Fig. 27I-P). In MPNs mice, 
chronic β3-AR agonist treatment improves exacerbated megakaryopoiesis by 
normalising Mk clusters (Fig. 28D-K) and atypical Mk distribution (Fig. 28A-C). 
Of note, despite MPN patients also showing improvement in Mk distribution after 
treatment (Fig. 28L-N), JAK2(V617F) allele burden and high platelet/myeloid 
blood counts are reportedly not decreased (Drexler et al., 2019). These 
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differences might be drug-dependent (different drugs were used for humans and 
mice), explained by different dose, stage and duration of treatment, and/or reveal 
differences in BM microenvironment between murine and humans. They also 
suggest that targeting single neuronal pathway might not be sufficient to 
rejuvenate overall haematopoiesis. Combining selective β3-AR agonist and β2-
AR antagonist could be a better therapeutic approach that could be tested in the 
future.            
 
Finally, the present study provides insights into the typical ‘’chicken or egg’’ 
question in ageing: microenvironmental alterations initiate HSC ageing or old 
HSCs trigger niche remodelling? Haematopoietic ageing features seem to emerge 
at distinct ages. In murine ageing, defective lymphopoiesis starts early at the age 
of 8 months old (Young et al., 2016), while increased platelet counts doesn’t seem 
to be pronounced until 18 months (Ho et al., 2019). BM Th+ sympathetic nerve 
fibres appear to be decreased in 12-month-olds mice (Maryanovich et al., 2018), 
but they are expanded in old (20 months-old) mice (Ho et al., 2019). Deficient 
β3-AR accelerates the loss of endosteal lymphoid-biased HSCs in 4-month-olds 
mice, but it does not exacerbate myeloid-skewing in the periphery of old mice 
(Fig. 23). In contrast, deficient β2-AR impairs megakaryopoiesis in both young 
and old mice, and double knockout of β2-AR and β3-AR recapitulates the 
haematopoietic phenotype of single β2-AR deficient mice. An adrenergic 
remodelling model contributing to imbalanced lymphoid/myeloid output through 
the microenvironment is proposed (Fig. 30): lack of β3-AR activity near 
endosteum initiates the contraction of endosteal niches, which attenuates 
lymphopoiesis, favours myeloid-bias and pushes HSCs away from the endosteum. 
Adrenergic switch from β3-AR to β2-AR promotes megakaryopoiesis, and 
possibly feedbacks to worsen the reduction of endosteal niches, since activation 
of β2-AR in osteoblasts is known to restrain bone formation (Kajimura et al., 
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2011). Deficient β3-AR also alters Mk niches by promoting Mk apposition to 
sinusoids, which might facilitate the proliferation of neighbouring HSCs. As a 
secondary outcome, HSCs might exit from quiescence and become more 
susceptible to acquire somatic mutations and initiate myeloid malignancies. 
Future studies are warranted to determine whether the aged niche can facilitate 
the expansion of myeloid clones carrying clonal-haematopoiesis-related somatic 
mutations. These clones become dominant during ageing and are candidate 
prerequisites for the development of many myeloid malignancies and 
cardiovascular diseases (Busque et al., 2012; Fuster et al., 2017; Genovese et al., 
2014; Jaiswal et al., 2014; Jaiswal et al., 2017; McKerrell et al., 2015; Xie et al., 
2014; Zink et al., 2017). Therefore, strategies targeting the microenvironmental 































Figure 29. Working model of adrenergic remodelling contributing to HSC 
ageing. 
Loss of β3-AR activity contracts endosteal niches by inhibiting NO production 
from the microenvironment (endothelial cells and/or stromal cells), which pushes 
HSCs away from the endosteum and favours myeloid-bias at the expense of 
lymphopoiesis. Adrenergic switch from β3-AR to β2-AR promotes Mk 
differentiation toward platelet production by increasing stromal cell-derived IL6. 
Accumulation of aged HSCs remodels the microenvironment by reinforcing β2-
AR activity overriding β3-AR activity, expanding non-endosteal niches and 
altering the proximal association of HSCs to Mks. LT-HSC: long-term 
haematopoietic stem cell. My-HSC: myeloid-biased haematopoietic stem cell. 
Ly-HSC: lymphoid-biased haematopoietic stem cell. TZVs: transitional zone 
vessels. MkP: megakaryocyte progenitor. Mk: megakaryocyte. NO: nitric oxide. 
NOS1: nitric oxide synthase 1. BMSC: bone marrow stromal cells. IL6: 
interleukin 6 
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5.2 Potential implications of the study 
Ageing is the major risk factor for haematological malignancies, such as MPNs, 
myelodysplastic syndrome (MDS), and acute myelogenous leukaemia (AML). 
The progression of myeloid neoplasms has been explained by clonal 
haematopoiesis: HSC clones acquiring leukaemia-associated somatic mutations 
are selected with age, take over normal HSCs and ultimately predispose 
haematological malignancies. HSC-autonomous dysregulations in ageing 
(Dykstra et al., 2011), such as epigenetic deregulation (Chambers et al., 2007), 
replication stress (Flach et al., 2014), deficient DNA repair (Rossi et al., 2007), 
and transition from canonical to non-canonical Wnt signalling (Florian et al., 
2013), are potential drivers for disease development. Old HSCs also suffer 
metabolic changes (Chandel et al., 2016; Ito and Suda, 2014), impaired autophagy 
(Ho et al., 2017) and altered protein homeostasis (Vilchez et al., 2014), which 
contribute to the decline of their regenerative potential. However, the selection 
pressure is not dependent on these intrinsic mechanisms alone. 
Microenvironment challenges also govern the expansion of HSC clones with 
specific functional properties. Recent studies suggest that HSCs are heterogenous, 
and HSC subpopulations might occupy different niches. For instance, lymphoid-
biased HSCs lodge near endosteum, whereas platelet/myeloid-biased HSCs are 
found adjacent with Mks in sinusoids. As a result, changes of endosteal and non-
endosteal niche size in ageing might favour the selection of platelet/myeloid-
biased HSCs over lymphoid-biased HSCs, leading to declined immunity and 
myeloid-skewing as an overall net outcome. The specific effect of β3-AR on 
lymphoid-biased HSCs supports the concept that clonal shift can result from 
relative loss of certain HSC clones rather than promoting the others. BM 
inflammation is another selection force. Traditional views believe that myeloid 
cells are a major source of inflammation, yet current studies argue that 
haematopoietic cells do not inflame the aged BM alone. Senescence of MSCs, 
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accumulation of adipocytes (Mancuso and Bouchard, 2019), decreased NO 
production and increased sympathetic innervation all contribute to  abnormal 
inflammation, which promotes myeloid expansion by indirectly facilitating niche 
remodelling, and positively selecting mutant and/or myeloid-biased HSC clones. 
Of note, leukaemia stem cells can also hijack normal HSC niches to reinforce the 
selection (Behrmann et al., 2018), suggesting an important interplay between 
HSCs and HSC-supporting niches. This study connects ageing and age-related 
cancers from the microenvironmental aspects, focuses on impaired neuronal 
regulation as one key example, and sheds lights on the possible implications on 
inhibiting myeloid clone expansion by targeting aberrant niche functions. 
 
Cardiovascular diseases are more frequent in the elderly. Blood cells 
overproduced in ageing, such as platelets and neutrophils, are essential players in 
cardiovascular diseases, suggesting a close relationship between cardiovascular 
dysfunctions and the haematopoietic systems. In atherosclerosis, for example, 
cardiovascular risk factors are known to promote myelopoiesis and 
megakaryopoiesis by providing external cues from the liver (Nagareddy et al., 
2018). Obesity indirectly causes myelopoiesis through liver macrophage-derived 
IL-1β (Nagareddy et al., 2014). Hyperglycaemia induces S100A8/A9 expression 
by neutrophils, which stimulates IL-6 and subsequent production of TPO from 
the liver to drive BM megakaryopoiesis (Lee and Bergmeier, 2017). Clinically, 
β-blockers (mainly targeting β1-AR and β2-AR) are widely used in 
cardiovascular medicine. The effect is reported to be mediated mainly through 
reducing platelet aggregation and/or hypertension (Bonten et al., 2014). However, 
the specific role of β2-AR found in the present study raises the possibility that β-
blockers might also affect BM Mk differentiation, which helps explain why some 
β-blockers are more effective than the others.     
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Over the last decade, efforts have been made to optimize platelet production in 
vitro in transfusion medicine. Challenges include inefficient Mk differentiation, 
poor production of end-stage mature cells and expensive cytokine cocktails. The 
present study applies an MSC-coculture system, in which minimum amounts of 
haematopoietic cytokines (only TPO and IL-1β) are required, successfully 
doubling the numbers of megakaryocytic cells from human cord blood-derived 
HSPCs under β2-AR agonist treatment. One future direction will be to test 
whether platelet production is also significantly enhanced followed by increased 
megakaryopoiesis. If yes, translating the setting into manufacturing processes 
will be a promising approach to treat thrombocytopenia. 
 
5.3 Conclusion remarks and the future scope 
In conclusion, this study demonstrates for the first time that different β adrenergic 
signals have microenvironment-dependent, but opposite effects on HSC lineage 
commitment during ageing. β2-AR promotes Mk differentiation through stromal 
cell-derived IL-6, whereas β3-AR regulates BM niche remodelling, balancing 
myeloid/lymphoid-biased HSCs partially through Nos1-NO-dependent manner. 
Premature ageing and myeloid disorders can be improved by targeting the 
microenvironment using β3-AR agonist. Herein, several interesting questions 
arise, and could potentially develop into follow-up projects in the future. Firstly, 
what are the cell types involved in aged haematopoiesis under β2-AR and/or β3-
AR regulation? Secondly, how does the proposed adrenergic switch from β3-AR 
to β2-AR happen during ageing? A possible answer to the questions is that cells 
highly expressing β2-AR replace those with high expression of β3-AR over time. 
Another possibility is that BM niche cells ubiquitously increase β2-AR while 
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decrease β3-AR upon ageing. These hypotheses require to be validated since the 
experiments were performed using global knockouts. Tissue-specific deletion of 
β2-AR/β3-AR in endothelial or mesenchymal lineages will be an ideal approach. 
Last but not the least, what is the role of β2-AR in MPNs? Generating β2-AR 
deficient mice with chimeric JAK2(V617F) BM cells, or treating MPNs mice 



















Figure 30. Schematic representation of the interplay between HSCs and the 
microenvironment during ageing.  
Loss of β3-AR activity contracts endosteal niches by decreasing endosteal vessels 
and the associated BMSCs, which disadvantage lymphoid-biased HSCs. As a 
secondary outcome, HSCs are pushed away from the endosteum to central 
marrow, favoring myeloid bias at the expense of lymphopoiesis. Accumulation of 
aged HSCs remodels the microenvironment by reinforcing adrenergic activity 
through β2-AR, expanding non-endosteal niches and promotes megakaryocyte 
differentiation toward platelet production. The damaged endosteal niches, 
increased sympathetic innervation on myeloid cells, and defective phagocytosis 
of senescent neutrophils by macrophages promote BM inflammation. An 
inflammatory cytokine storm positively selects myeloid-biased HSCs clones over 









Table 6. Summary of BM microenvironmental alterations during ageing. 
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